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EXECUTIVE SUMMARY 
 
1 INTRODUCTION 
1.1 Aims of the review 
To determine the effectiveness of long-term harm reduction approaches without the prior 
intention of quitting (ie reducing consumption without the aim of quitting), with and without 
assistance. 
1.2 Research questions 
 How effective are pharmacotherapies in helping people cut down or abstain from 
smoking, temporarily or indefinitely without the aim of quitting?  
 How effective are different combinations of nicotine replacement therapy (NRT) products 
in helping people cut down or abstain from smoking, temporarily or indefinitely without 
the aim of quitting? 
 How effective are ‘nicotine-containing products’ in helping people cut down or abstain 
from smoking, temporarily or indefinitely without the aim of quitting? 
 How effective are behavioural support, counselling, advice or self-help (with or without 
pharmacotherapy) in helping people to cut down or abstain from smoking, temporarily or 
indefinitely, without the aim of quitting? 
 Is there an optimal period to help people cut down or abstain (temporarily or indefinitely) 
from smoking without the aim of quitting? 
 Is it more or less effective to draw up a schedule to help people cut down or abstain from 
smoking, temporarily or indefinitely, without the aim of quitting? 
 Do some tobacco harm-reduction approaches have a differential impact on different 
groups (for example, people of different ages, gender, socio-economic status (SES) or 
ethnicity)? 
 Are there any unintended consequences from adopting a tobacco harm-reduction 
approach; for example, does it deter people from trying to cut down or abstain from 
smoking, temporarily or indefinitely? 
 
1.3 Background 
Although smoking rates have declined sharply in the last 30 years, this decline has slowed in 
recent years. In the past, public health strategies have focused on discouraging people from 
starting to smoke and helping smokers to quit the habit completely. There remains a group of 
smokers who either want to quit but feel unable to stop abruptly or otherwise are not willing or 
able to quit but may be prepared to reduce the amount they smoke. The healthiest course of 
action for all smokers is to stop smoking but harm reduction measures attempt to limit the risks 
by reducing exposure to the toxic chemicals found in tobacco smoke (Royal College of 
Physicians, 2007). NICE has been asked by the Department of Health to develop guidance on 
‘Tobacco – harm reduction approaches to smoking’. The guidance will be underpinned by five 
evidence reviews. Review 1 considered the safety, risk and pharmacokinetics of tobacco harm 
reduction (THR) technologies (Jones et al, 2011). The second reviewed the effectiveness of 
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interventions for ‘cutting down to quit’. This review is the third in the series and considers 
interventions for long term smoking reduction without the intention of quitting. Review 4 will be 
a companion to reviews two and three; looking at barriers and facilitators to harm-reduction 
approaches and the series will be completed with a health economic analysis of THR 
approaches.   
2  METHODS 
 A systematic review of effectiveness evidence to address the above review question has been 
undertaken. A wide range of databases and websites was searched systematically, supplemented by 
grey literature1 searches. Searches were carried out in August 2011 to identify relevant studies in the 
English language published between 1990 and 2011. A follow-up database search was conducted in 
November 2011. 
All populations of all ages were included other than pregnant women; with a particular focus on those 
who have been identified as being more likely to smoke, at increased health risk from smoking and/or 
experiencing health inequalities.   
Interventions considered were: 
 Pharmacotherapies that are licensed for cutting down, temporary abstinence or harm 
reduction (currently only  nicotine replacement therapy is licensed for these indications)  
 Other non-tobacco nicotine containing products (e-cigarettes and topical gels) 
 behavioural support, counselling, advice or self help.   
All smoking-related outcomes were considered. 
Study selection was conducted independently in duplicate. Quality assessment was undertaken by one 
reviewer and checked by a second, with 20% of papers being considered independently in duplicate. 
Both processes were tested for inter-rater reliability and monitoring. Data was extracted by one 
reviewer and checked by a second.   
A narrative summary of the evidence was completed along with a meta-analysis of findings where 
feasible. 
3. RESULTS 
61 papers were included, comprising 45 individual studies and 1 systematic review.   
The quality of the included studies was variable although there was a good body of consistent 
evidence in some areas. Five of the included randomised controlled trials (RCTs) were deemed to be of 
high quality (Bolliger 2000 ++, Chan 2011 ++, Glasgow 2009 ++, Hovell 2000 ++, Warner 2005 ++). Of 
the remaining studies there were 2 RCTs, 5 partial RCTs, 17 quasi-RCTs (unclear or inappropriate 
allocation concealment), 3 non-RCTs, 2 controlled before and after (CBA) studies, 10 uncontrolled 
before and after (UBA) studies and 1 secondary analysis. The UBAs and secondary analysis were all 
considered to be of low quality. 
Five studies were carried out in the UK (Foulds 1992 +, Gray 2005 −, Irvine 1999 +, McCambridge 2005 
+, Munday 1993 −, Walker 2009 −) and six in countries with smoking treatment programmes similar to 
those in the UK: three in Australia (Borland 1999 +, Kelly 2006 +, Wakefield 2002 +), two in Denmark 
                                                          
1
 Technical or research reports, doctoral dissertations, conference papers and official publications.   
THR 3.3 Review 3: Effectiveness of long-term tobacco harm reduction approaches – Executive Summary and Review  
 
6  
 
(Pisinger 2005 −, Wennike 2003 +) and one in Spain (Jimenez-Ruiz 2002 −).  Twenty three of the 
remaining studies were conducted in the USA. Of these 11 were community based and feasible in the 
UK. 
In general there was little information on specific socio-economic groups with only three studies 
looking at lower SES populations (Hovell 2000 ++, Kelly 2006 +, Wakefield 2002 +). 
See Table 1 and Appendix A for details of all the included studies.
4. EVIDENCE STATEMENTS 
Q1. How effective are pharmacotherapies in helping people cut down or abstain from smoking 
temporarily or indefinitely without the aim of quitting? 
Evidence Statements:  
1.1 There is strong to moderate evidence from nine studies - two RCTs, five quasi-RCTs and 
two UBAs - (Bolliger 2000 ++, Etter 2007 +, Batra 2005 +Hatsukami 2005 −, Jiménez-Ruiz 
2002 −, Kralikova 2009 +, Rennard 1990 −, Rennard 2006 +, Wennike 2003 +) that NRT 
(gum or inhaler) versus placebo is effective in reducing cigarette consumption across 
multiple outcome measures and in eventual abstinence in smokers not looking to quit.   
1.2  There is strong to moderate evidence from a meta-analysis of three RCTs and one quasi-
RCT (Bolliger 2000 ++, Chan 2011 ++, Etter 2007 +, Wennike 2003 +) looking at ≥50% point 
prevalence reduction in CPD compared to baseline, that NRT, with or without a brief MI 
component, is more effective than placebo with a relative risk  (RR) = 1.46 (95% CI 1.20, 
1.78), with a number needed to treat (NNT) of 13 (95% CI 10, 20). A sensitivity analysis 
excluding Chan 2011 ++ (which added a brief MI component to NRT) resulted in RR=1.35 
(95% CI: 1.10, 1.65) and an NNT of 17 (95% CI 10, 50). Smoking reduction was verified by 
CO except in Etter 2007 +.  
1.3 There is moderate evidence from a meta-analysis of one RCT and 2 quasi-RCTs (Bolliger 
2000 ++, Batra 2005 +, Wennike 2003 +) that NRT is more effective than placebo in 
percentage reduction in cigarettes per day from baseline with a risk difference (RD) of 
−13.85 (95% CI: −25.5, −2.45). 
1.4 There is unclear evidence from a meta-analysis of one RCT and three quasi-RCTs (Bolliger 
2000 ++, Batra 2005 +, Kralikova 2009 +, Wennike 2003 +) for the efficacy of NRT for any 
sustained CPD reduction compared to baseline with an RR=2.45 (95% CI: 0.9, 6.4). In a 
sensitivity analysis that excluded Kralikova 2009 + for significant heterogeneity, NRT 
increased the chance of a sustained smoking reduction RR=3.38 (95% CI 1.7, 6.6), with an 
NNT of 17 (95% CI 13, 34), and no evidence of between-study statistical heterogeneity.   
1.5 There is strong evidence from a meta-analysis of nine studies (three RCTs and six quasi 
RCTs) investigating cessation in populations not looking to quit (Bolliger 2000 ++, Chan 
2011 ++, Etter 2007 +, Batra 2005 + , Carpenter 2004 +,  Joseph 2008 +, Kralikova 2009 +, 
Rennard 2006 +, Wennike 2003 +) that NRT with or without associated behavioural 
interventions has a statistically significant effect: RR=1.96 (95% CI 1.36, 2.80) with an NNT 
of 20 (95% CI 13, 34). A sensitivity analysis excluding studies with a behavioural 
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component (Carpenter 2004 +, Chan 2011 ++, Joseph 2008 +), found a similar result for 
NRT alone: RR=1.93 (95%CI 1.26, 2.96) and an NNT of 20 (95% CI 13, 34). 
 1.6 There is moderate evidence from one RCT (Warner 2005 ++) that nicotine patch versus  
placebo is effective in reducing post-operative smoking consumption, a statistically 
significant self-reported reduction was observed 30 days post-operation but this was not 
maintained at 6 months. 
1.7 There is weak evidence from five studies (Benowitz 1998 −, Fagerström 1997 −, Foulds 
1992 +, Hatsukami 2007 −, Pickworth 1994 −) that a nicotine patch may help reduce ad 
libitum cigarette smoking. In the only controlled study (Foulds 1992 +) the result was not 
statistically significant. 
The majority of the evidence is applicable to the UK as the studies are community based and 
feasible in UK settings, although Batra 2005 + involved participants making several clinic visits 
and  Foulds 1992 + was in a laboratory setting. Warner 2005 ++ was conducted within a specific 
population (patients undergoing elective surgery). 
 
Q2. How effective are different combinations of NRT products in helping people cut down or abstain 
from smoking, temporarily or indefinitely without the aim of quitting? 
Evidence Statement:  
2.1  No studies were found that looked at combinations of NRT products for helping people to 
cut down or abstain from smoking, temporarily or indefinitely without the aim of quitting.  
 
Q3. How effective are ‘nicotine-containing products’ in helping people cut down or abstain from 
smoking, temporarily or indefinitely without the aim of quitting? 
For the purposes of this review ‘nicotine containing products’ were defined as ‘electronic nicotine 
delivery systems’ (sometimes known as ‘electronic cigarettes’ or ‘e-cigarettes’) and topical gels. 
Currently these products are not regulated by the Medicines and Healthcare products Regulatory 
Agency (MHRA). 
Evidence Statement:  
3.1   Very weak evidence from one UBA (Polosa 2011−) suggests that e-cigarette availability 
can help smokers reduce.  
This evidence may be applicable to the UK as it is community based and feasible in a UK setting.  
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Q4. How effective are behavioural support, counselling, advice or self-help (with or without 
pharmacotherapy) in helping people to cut down or abstain from smoking, temporarily or 
indefinitely, without the aim of quitting? 
 
Evidence Statements:  
4.1 There is consistent evidence from seven studies (2 RCTs, 4 quasi-RCTs and 1 CBA) (Horn 
2007 +, McCambridge 2005 +, Kelly 2006 +, Audrain-McGovern 2011 +, Davis 2011 +, 
Gulliver 2008 +, Gray 2005 −) that motivational interviewing compared with other 
behavioural methods or with no support and whether provided in single or multiple 
sessions, is not effective in helping people to reduce smoking levels. This evidence 
applies to healthy adolescents and adults, with no statistically significant between group 
differences reported across any of the studies reviewed. Weak evidence also exists for 
the lack of effectiveness of motivational interviewing for adolescent drug users 
(McCambridge 2005 +, Gray 2005 −) and military veterans with psychiatric problems 
(Gulliver 2008 +), with these studies again finding no significant between group 
differences for the outcomes reported.   
4.2 There is strong evidence from a meta-analysis of two RCTs and three quasi-RCTs (Horn 
2007 +, McCambridge 2005 +, Audrain McGovern 2011 +, Davis 2011 +, Kelly 2006 +) 
that motivational interviewing, compared with other behavioural methods or with no 
support and provided in single or multiple sessions, is not effective for smoking cessation 
in populations unable or unwilling to stop smoking: RR 1.34 (95% CI 0.75, 2.39; p=0.32). 
This is at variance with findings of a Cochrane systematic review of MI for smoking 
cessation (Lai 2010). The addition of NRT to a motivational component (Chan 2011 ++, 
Carpenter 2004 +) may improve the likelihood of abstinence: RR 3.09 (95% CI 1.06, 9.01; 
p=0.04).  
4.3 There is moderate evidence from a large well-conducted RCT (Chan 2011++) that NRT 
combined with a motivational component is effective, with a significant CO-validated 
≥50% 7-day point prevalence reduction rate. 
4.4 There is strong to moderate evidence from four studies (1 RCT, 1 quasi-RCT, one non-RCT 
and a CBA) designed to reduce the impact of environmental tobacco smoke on children 
(Hovell 2000 ++, Irvine 1999 +, Wakefield 2002 +, Fossum 2004 −) of no effect for a 
variety of behavioural methods versus standard care in reducing parental smoking. This 
evidence applies to parents of children with asthma (Irvine 1999 +, Wakefield 2002 +) as 
well as to parents of healthy children (Hovell 2000 ++, Fossum 2004 −). 
4.5 There is moderate evidence from two RCTs (Hanson 2008 +, Joseph 2008 +) and one UBA 
(Hurt 2000 −) that counselling combined with nicotine replacement therapy is not 
effective in helping adolescents (Hanson 2008 +) or adults (Hurt 2000 −, Joseph 2008 +) 
to reduce their cigarette consumption or to ultimately quit.  There were no differences at 
follow-up between intervention and control groups for any smoking related oumes. 
4.6 There is moderate evidence from one RCT (Glasgow 2009 ++) that telephone counselling 
is an ineffective approach to reducing cigarette consumption.  At the 12 month follow-up 
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there were no significant differences between intervention and control groups in terms 
of numbers reducing their daily cigarette consumption by ≥50% or in carbon monoxide 
levels. 
4.7 There is moderate evidence from one quasi-RCT (Riley 2002 +) that computer-aided and 
manual-aided approaches to assist with reduction had similar effect sizes. Twelve 
months after the start of the study there were no differences between groups in smoking 
reduction, and although more participants in the computer-aided group had made a quit 
attempt than in the manual-aided group, this difference was not statistically significant. 
4.8 There is moderate evidence from one systematic review of pre-operative smoking 
interventions (Thomsen 2010 +) that counselling combined with NRT increases smoking 
cessation at the time of surgery for both brief and intensive interventions. However only 
intensive interventions were effective at 12 month follow-up. RR 2.96 (95% CI 1.57, 5.55) 
for two trials.  
 4.9 There is weak evidence from one quasi-RCT (Carpenter 2004 +) that both NRT aided 
reduction and motivational treatment are more effective than no treatment both in 
terms of reducing smoking and ultimately quitting. There were no significant differences 
between the two intervention groups on any outcomes (all self-reported).  This finding is 
at odds with those reported in the other behavioural studies. 
4.10 There is weak evidence from one RCT (Schleicher 2010 +) and one small UBA  
(Roll 1998−) that cognitive behavioural therapy is not effective in helping smokers to 
reduce their cigarette consumption or to reduce and ultimately quit.  
4.11 There is weak evidence from one quasi-RCT (Cunningham 2006 +) that providing safer 
smoking tips can have a marginal effect on reduction.  At three months follow-up those 
who received safer smoking tips self-reported a small reduction in the number of 
cigarettes smoked compared to those in the control condition (p=0.05). Overall levels of 
change in cigarettes per day were small, however, and the mean number of cigarettes 
per day remained high in both groups at follow-up. 
4.12 There is weak evidence from one quasi-RCT (Borland 1999 +) that a self-help programme 
to assist smokers in coping with workplace smoking bans may not be effective.  At the six 
month follow-up there were no differences between groups on any of the outcomes 
assessed. 
4.13 There is weak evidence from one non randomised study and one UBA (Munday 1993 –, 
Walker 2009 –) that brief advice alone for pre-operative smoking cessation is not 
effective in achieving pre-operative abstinence. 
4.14 There is very weak evidence from a UBA (Carpenter 2007–) that knowledge of alpha-1-
antitrypsin (AAT) deficiency is effective in influencing quit attempts and cigarette 
consumption. 
4.15 There is very weak evidence from two UBAs (Griffiths 2010 –, Tidey 2002 –) that 
behavioural support combined with NRT is effective in reducing smoking among adults 
with mental illness. 
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4.16 There is very weak evidence from one quasi-RCT (Riggs 2001 –) of no difference between 
NRT and hierarchical reduction versus NRT and increased inter-cigarette interval in 
reducing smoking. 
4.17 There is very weak evidence from one small UBA (Beard 2012) that a personal CO 
monitor is not effective in reducing CPD and encouraging abstinence. 
The majority of evidence is applicable to the UK as the studies are feasible in UK settings. 
However Carpenter 2007 –, Griffiths 2010 –, Hanson 2008 +, Tidey 2002 – are noted to have 
issues regarding applicability. Studies of specific populations included Kelly 2006 +, Audrain-
McGovern 2011 +, Hanson 2008 +, Horn 2007 + (adolescents); Gray 2005 –, McCambridge 2005 
+ (adolescent drug users); Gulliver 2008 + (military veterans); Griffiths 2010 –,Schleicher 2010 
and Tidey 2002 – (mental health); Munday 1993 –, Thomsen 2010 +, Walker 2009 – (patients 
undergoing elective surgery); Hovell 2000 ++, Fossum 2004 –, Irvine 1999 +, Wakefield 2002 + 
(parents).   
 
Q5. Is there an optimal period to help people cut down or abstain (temporarily or indefinitely) from 
smoking without the aim of quitting? 
Evidence Statement:  
5.1 No studies were found that looked at the effect of different reduction periods in helping 
people to cut down or abstain (temporarily or indefinitely) from smoking. 
 
Q6. Is it more or less effective to draw up a schedule to help people cut down or abstain from 
smoking, temporarily or indefinitely, without the aim of quitting? 
Evidence Statements:  
6.1 Weak evidence from 2 quasi-RCTs and 2 UBAs (Riggs 2001 −, Riley 2002 +, Hatsukami 
2005 −, Hurt 2000 −) suggests the use of a schedule may assist in reducing smoking.  
Schedules included week on week reduction (Hatsukami 2005 −, Hurt 2000 −), increased 
inter-cigarette interval or selective elimination (Riggs 2001 −, Riley 2002 +). 
6.2 There is limited evidence from 2 quasi-RCTs (Riggs 2001 −, Riley 2002 +) of no difference in 
effect between different types of schedule (increasing inter-cigarette intervals or selective 
elimination). 
The evidence is partially applicable to people in the UK since all four studies were community 
based (in the USA) and are feasible in UK settings.  
 
Q7. Do some tobacco harm-reduction approaches have a differential impact on different groups (for 
example, people of different ages, gender, socio-economic status or ethnicity)? 
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Evidence Statements:  
7.1 There is moderate evidence from five studies (2 RCTs, 2 quasi-RCTs, 1 CBA) (Horn 2007 +, 
McCambridge 2005 +, Audrain McGovern 2011 +, Kelly 2006 +, Gray 2005 −) of no effect 
for motivational interviewing interventions in reducing smoking in adolescents. 
7.2 There is weak evidence from one quasi-RCT (Hanson 2008 +) that cognitive behavioural 
therapy (CBT) plus NRT is not effective in reducing smoking among adolescents. 
7.3 Weak evidence from one quasi-RCT in the USA (Audrain McGovern 2011 +) comparing a 
multi-session intensive MI intervention to multiple sessions of brief structured advice,  
suggests that white adolescents are significantly less likely than black adolescents to 
attempt to reduce or quit smoking. 
7.4 Moderate evidence from one high quality RCT (Chan 2011 ++) indicates that MI plus NRT 
was effective in reducing smoking in adult Chinese smokers who had previously failed to 
quit.  
7.5  There is weak evidence from one quasi-RCT (Kelly 2006 +) of no effect of MI on Australian 
adolescents from lower SES families. 
7.6 Moderate evidence from 1 RCT and 1 non-randomised study (Hovell 2000 ++, Wakefield 
2002 +) found no evidence of effect for behavioural interventions in reducing parental 
smoking in low income families.  
7.7 There no evidence of sustained effect of behavioural interventions from 4 studies (1 RCT 
and 3 UBAs) (Schleicher 2010 +, Tidey 2002 –, Roll 1998 –, Griffiths 2010 –) in mental 
health populations.  
7.8 There is very weak evidence from two small UBAs (Tidey 2002 –, Roll 1998 –) of a ‘during 
treatment effect’ on carbon monoxide-verified reduction in mental health populations for 
contingency management with or without NRT. 
The evidence is partially applicable to people in the UK.  McCambridge 2005 + and Gray 2005 –
were both based in the UK, and Kelly 2006 + and Wakefield 2002 + were based in Australia 
where there is a similar smoking treatment service to the UK. Of the remaining studies, Chan 
2011 ++, Griffiths 2010 – and Hovell 2000 ++ were based in the community and interventions 
may be feasible for the UK.    
 
Q8. Are there any unintended consequences from adopting a tobacco harm-reduction approach; for 
example, does it deter people from trying to cut down or abstain from smoking, temporarily or 
indefinitely? 
Evidence Statements:  
8.1 There is strong evidence from eight studies reporting usage of NRT for periods between 
six months and five years (Batra 2005 +, Bollinger 2000 ++,   Etter 2007 +, Jiménez-Ruiz 
2002 –, Joseph 2008 +, Kralikova 2009 +, Rennard 2006 +, Wennike 2003 +) to suggest 
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that NRT is generally well tolerated long term with severe side effects being relatively rare. 
8.2 There is moderate evidence from two quasi-RCTS (Carpenter 2004 +, Wennike 2003 +) 
that harm reduction interventions do not deter smokers from wishing to quit. 
8.3 There is weak evidence from a single UBA (Polosa 2011 –) that frequent adverse events 
are reported by e-cigarette users.  This finding supports the conclusions from Review One 
(Toxicity) that more evidence is required concerning the safety of e-cigarettes. 
Adverse event studies are likely to be applicable to the UK. 
 
 
 
5. DISCUSSION 
This review contains a large body of evidence of relevance to long term harm reduction without the 
prior aim of quitting.  
Five studies were conducted in the UK, and six in countries with similar smoking treatment 
programmes. In general, applicability to the UK was good with many other studies based in the 
community.   
The quality of the included studies was variable with a wide variation in time periods and outcomes. 
There was a good body of consistent evidence for some topics and outcomes for NRT studies 
(measures of CPD, ≥50% reduction and continuous or point-prevalent abstinence) were generally 
consistent. By contrast, reduction outcomes for behavioural studies varied considerably and it was not 
possible to conduct meta-analyses other than for abstinence. Reduction outcomes were generally self-
reported so there is little information on reduction in exposure. However, where studies identify 
abstinence at follow-up and report this outcome, it is generally biochemically verified.  
Participant motivations were difficult to ascertain in some studies. Thus, the scope of the review 
included studies that were designed as long term harm reduction studies, as well as those where the 
included participants did not wish to quit smoking. 
All six randomised/quasi-randomised studies investigating the use NRT in the general population were 
either industry sponsored (Bolliger 2000 ++, Batra 2005 +, Kralikova 2009 +, Rennard 2006 +, Wennike 
2003 +), or the authors had financial ties to industry (Etter 2007 +).  As noted in Review 2, authors 
declared sources of funding and any potential conflicts of interest. However, a 2003 meta-analysis of 
RCTs included in a Cochrane review of smoking cessation interventions concluded that “Compared 
with independent trials, industry-supported trials were more likely to produce statistically significant 
results and larger odds ratios. These differences persisted after adjustment for basic trial 
characteristics.” (Etter 2003) The authors suggested that this difference may be the result of 
publication bias.  
By contrast, potential conflicts of interest were only identified in one behavioural study (Riley 2002 +) 
in which the computerised scheduled reduction intervention had been developed and was being 
marketed by a company employing the authors. 
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Nine of the behavioural studies (three RCTs, five quasi-RCTs and one CBA) included a ‘motivational 
interview’ component as part of the intervention (Chan 2011++, Horn 2007 +, McCambridge 2005 +, 
Audrain-McGovern 2011 +, Carpenter 2004 +, Davis 2011 +, Gulliver 2008 +, Kelly 2006 +,  
Gray 2005 −); two studies combining that component with NRT (Chan 2011 ++, Carpenter 2004 +). The 
component ranged from a single brief interview to multiple intensive sessions. There appeared to be 
little difference in outcome between brief and intensive interventions. Fidelity to the principles and 
practice of motivational interviewing (Miller 2002) was also considered. Six of the seven studies 
looking at motivational interviewing alone identified key elements of principles and practice. Fidelity 
was unclear in both studies combining a motivational component with NRT.  
Overall, the evidence within the review suggests that:  
 Across all studies of NRT versus placebo where reduction is an intended outcome, meta-
analyses indicate significant benefits from NRT. 
 NRT may also be effective for abstinence in the longer term in populations not looking to quit. 
 NRT supplementation may help reduce ad libitum smoking (where there is no instruction to 
reduce) but the evidence base is weak.  
 No evidence comparing combinations of NRT was found but it appears that there are no clear 
differences in effectiveness between different types of medication and some modest evidence 
that offering smokers a choice of medication may enhance efficacy. 
 Nicotine patch is effective in reducing post-operative smoking consumption in the short term 
but this is not maintained long term. 
 Evidence for the value of e-cigarettes to date is available only from a single UBA study and, 
although suggestive of benefit, no conclusions can be drawn as yet. We note that the MHRA is 
currently considering whether to regulate e-cigarettes and other nicotine-containing products. 
 Two studies suggest NRT combined with a brief motivational component may be effective for 
abstinence in populations not looking to quit. However, the impact of the motivational 
component is unclear.    
 There is consistent evidence that motivational interviewing, either in single or multiple sessions, 
is not effective as a long-term harm reduction strategy.  
 MI does not appear to be effective for abstinence in populations unable or unwilling to quit. This 
is at variance with the evidence from a Cochrane systematic review looking at the effect on 
abrupt cessation (Lai 2010); which found some evidence that MI may assist abstinence. The 
reason for this variance is not clear, although it may reflect the impact of the two statistically 
significant studies - Hollis 2007 and Soria 2006. In the first, which contributed considerable 
weight to pooled analyses, study participants had to be motivated to quit. In the second study 
bupropion was provided to a small proportion of the MI group, which may have skewed the 
results.  
 The evidence available for other types of behavioural intervention is weaker but it is also 
suggestive of no benefit. 
 Both brief and intensive pre-operative smoking interventions, combining counselling with NRT, 
increase smoking cessation at the time of surgery. However only intensive interventions were 
effective long term. 
THR 3.3 Review 3 - Effectiveness of tobacco harm reduction approaches without the prior intention of quitting with and without 
assistance 
 
 
 
14  
 
 There is no evidence of effect on parental smoking levels from interventions to reduce 
environmental tobacco smoke. Results do not appear to vary between parents of asthmatics 
and those with generally healthy children. 
 No evidence was found to suggest an optimal reduction period. 
 Limited weak evidence suggests that scheduled smoking reduction may be more effective than 
non-scheduled smoking reduction; although there do not appear to be differences in effect 
between types of scheduled reduction.  
 There is very little evidence to distinguish the effectiveness of interventions across socio-
economic groups.  
 The small amount of evidence available suggests that harm reduction interventions do not deter 
smokers from wishing to quit. More evidence of smokers’ views is likely to be provided within 
the barriers and facilitators review (Review 4). 
 Longer-term NRT use appears to be well tolerated over periods between six months and five 
years with severe side effects being relatively rare. 
Further research is needed in a number of areas: the differential effects for socio-economic and ethnic 
groups, the impact of different NRT combinations and the efficacy of e-cigarettes, the effect of 
intensity of the intervention.  
THR 3.3 Review 3 - Effectiveness of tobacco harm reduction approaches without the prior intention of quitting with and without 
assistance 
 
 
 
15  
 
ABBREVIATIONS  
AAT alpha-1-antitrypsin  
BI Instruction in deep breathing 
BP Blood pressure 
C  Control group 
CES-D  Center for Epidemiological Studies-Depression Scale 
CBA Controlled before and after study 
CM  Contingency management  
CO  Carbon monoxide 
CPD  Cigarettes per day 
CPW Cigarettes per week 
CSGR Computerised schedule gradual reduction 
DH  Department of Health 
DSM Diagnostic and Statistical Manual of Mental Disorders 
ED Emergency Department 
ETS Environmental tobacco smoke 
FTND  Fagerström Test for Nicotine Dependence  
FTQ Fagerstrom Tolerance Questionnaire  
GEE Generalised estimating equation 
GP   General Practitioner 
HMO Health management organisation 
HR Hierarchical Reduction  
HR-E  Hierarchical reduction – easiest first 
HR –H  Hierarchical reduction – hardest first 
I  Intervention group 
ICI Increased Inter-cigarette interval 
ITT Intention to treat  
MANOVA Multiple analysis of variance 
MET Motivational enhancement therapy 
MHRA Medicines and Healthcare products Regulatory Agency 
MI Motivational interviewing OR myocardial infarction 
MNWS Minnesota Nicotine Withdrawal Scale 
NA Nicotine Anonymous 
NCP Nicotine containing product 
NHS   National Health Service 
NICE  National Institute for Health and Clinical Excellence 
NIDA National Institute of Drug Abuse 
N-P Nicotine placebo difference 
NNT Number needed to treat 
NRT  Nicotine replacement therapy 
NS Not significant 
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NTIS  National Technical Information Service 
OR   Odds ratio 
QFL Quit for Life 
QSU Questionnaire on Smoking Urges 
POD Post-operative day 
PPM Parts per million 
RBC Red blood cell 
RT Randomised trial (all intervention arms, no control) 
RCT  Randomised controlled trial 
SA Secondary analysis 
SBA Structured brief advice 
SC South Carolina 
SER Selective elimination reduction 
SES Socio-economic status 
IS incentive spirometer  
SR Scheduled reduction 
ST  Standard treatment 
UBA Uncontrolled before and after study 
VAS Visual Analogue Scale 
WBC White blood cell 
WHO World Health Organisation 
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1 INTRODUCTION 
1.1 Aims of the review 
To determine the effectiveness of long-term harm reduction approaches without the prior 
intention of quitting (ie reducing consumption without the aim of quitting), with and without 
assistance. 
 
1.2 Research questions 
 How effective are pharmacotherapies in helping people cut down or abstain from 
smoking, temporarily or indefinitely without the aim of quitting?  
 How effective are different combinations of nicotine replacement therapy (NRT) products 
in helping people cut down or abstain from smoking, temporarily or indefinitely without 
the aim of quitting? 
 How effective are ‘nicotine-containing products’ in helping people cut down or abstain 
from smoking, temporarily or indefinitely without the aim of quitting? 
 How effective are behavioural support, counselling, advice or self-help (with or without 
pharmacotherapy) in helping people to cut down or abstain from smoking, temporarily or 
indefinitely, without the aim of quitting? 
 Is there an optimal period to help people cut down or abstain (temporarily or indefinitely) 
from smoking without the aim of quitting? 
 Is it more or less effective to draw up a schedule to help people cut down or abstain from 
smoking, temporarily or indefinitely, without the aim of quitting? 
 Do some tobacco harm-reduction approaches have a differential impact on different 
groups (for example, people of different ages, gender, socio-economic status or 
ethnicity)? 
 Are there any unintended consequences from adopting a tobacco harm-reduction 
approach; for example, does it deter people from trying to cut down or abstain from 
smoking, temporarily or indefinitely? 
 
1.3 Background 
Although smoking rates have declined sharply in the last 30 years, this decline has slowed in 
recent years with prevalence rates levelling off at 21% in England in 2008 (Robinson and Bugler, 
2010) and 24% in Wales in 2009 (Welsh Assembly Government, 2010). Fourteen percent of 
adults in managerial and professional households in England reported that they currently 
smoked, compared with 29% in routine and manual households; the corresponding figures for 
Wales were 15% versus 31%.   
People from routine and manual occupational groups take in more nicotine from cigarettes than 
more affluent people (Jarvis 2010). This increases their exposure to the other toxins in tobacco 
smoke and, thus, increases their risk of smoking-related disease. Higher nicotine exposure can 
also make it harder for them to quit and they are more likely to cut down first rather than quit 
smoking ‘abruptly’ (Siahpush et al. 2010). Exposure to increased levels of nicotine, carbon 
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monoxide and other toxins can also result from 'roll-your-own' as compared to manufactured 
cigarettes (UK Department of Health Tobacco Policy Team 2003). 
In the past, public health strategies have focused on discouraging people from starting to smoke 
and helping smokers to quit the habit completely. There remains a group of smokers who either 
want to quit but feel unable to stop abruptly or otherwise are not willing or able to quit but may 
be prepared to reduce the amount they smoke. The healthiest course of action for all smokers is 
to stop smoking but harm reduction measures attempt to limit the risks by reducing exposure to 
the toxic chemicals found in tobacco smoke (Royal College of Physicians, 2007). 
Harm reduction is defined as ‘policies, programmes, services and actions which aim to reduce 
the harm to individuals, communities and society that are associated with the use of drugs’. 
Such measures are pragmatic, recognising that the reduction of harms may be more feasible 
than complete elimination of drug use (UK Harm Reduction Alliance).  
In relation to tobacco use specifically a product is considered harm reducing ‘if it lowers total 
tobacco-related mortality and morbidity, even though use of that product may involve 
continued exposure to tobacco related toxicants’ (Stratton et al, 2001).  Harm reduction can 
refer both to those who want to quit but feel unable to do so abruptly, and those who smoke 
and do not feel willing or able to quit but who want to reduce the harm that smoking is doing to 
their health, or to the health of those around them (Royal College of Physicians, 2007). 
Smokers continue to smoke predominantly due to nicotine addiction, but in so doing expose 
themselves to a large number of chemicals, many of which are established carcinogens. Tobacco 
smoke contains over 4,000 chemicals, including carbon monoxide, nitrosamines, polycyclic 
aromatic hydrocarbons, nitrogen oxides, hydrogen cyanide and heavy metals. Furthermore, 
exposure to second-hand smoke in the home causes an estimated 11,000 deaths a year in the 
UK from lung cancer, stroke and ischaemic heart disease (Jamrozik 2005).   
The Royal College of Physicians estimate that if only 0.4% of the population of smokers in the UK 
switch from smoking to less harmful nicotine sources each year, this would save approximately 
25,000 lives in 10 years. In addition, the Department of Health’s (DH) publication ‘Drug Misuse 
and dependence: UK guidelines on clinical management’ states that: ‘Given the high rates of 
smoking and the low quit rates in drug misusers, it may be reasonable to consider harm 
reduction approaches to smoking such as replacing cigarettes with clean nicotine in the form of 
patches for some of the day. This may be particularly useful in alleviating the symptoms of 
tobacco withdrawal while a patient is within a residential or inpatient drug treatment facility’ 
(DOH, 2007). 
A systematic review of the evidence (Pisinger 2007) found that the limited data available suggest 
that a substantial reduction in smoking (defined in many studies as ≥50% reduction in baseline 
smoking) improves several cardiovascular risk factors and respiratory symptoms. In addition, 
smoking reduction is associated with a 25% decline in biomarkers and incidence of lung cancer 
and a small, non significant, increase in birth weight. 
Although harm reduction strategies have been successful in other areas, when applied to 
tobacco they are controversial. For example there may be unintended consequences of 
adopting harm reduction measures such as ex-smokers relapsing to the harm reduction option 
and young people starting off with the harm reduction option in the belief that it is safer. In such 
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cases it is possible the benefits may be overwhelmed by more widespread uptake of harm 
reduction measures. Another criticism levelled against harm reduction measures is that they 
represent an admission of defeat and still leave the smoker exposed to harm (Bates, 2002). 
The National Institute for Health and Clinical Excellence (NICE) has been asked by the 
Department of Health to develop guidance on ‘Tobacco – harm reduction approaches to 
smoking’. This guidance will provide recommendations for good practice based on the best 
available evidence of effectiveness, including cost effectiveness. It is aimed at professionals, 
commissioners and managers with public health as part of their remit. It is especially aimed at 
those involved in smoking cessation services within the NHS, local authorities and the wider 
public, private, voluntary and community sectors. It will also be of interest to members of the 
public, especially people who want to stop or cut down the amount they smoke. 
The guidance will make recommendations on approaches to help smokers of all ages who: 
 want to quit smoking but feel unable to do so ‘abruptly’ (that is, they want to cut down 
before quitting) 
 are not willing or able to quit, but want to reduce the harm that smoking is doing to their 
health (or to the health of those around them) 
 want to quit smoking but are not willing or able to stop using nicotine 
 want to stop smoking temporarily, for example, while at work.  
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2.  METHODS 
2.1 Literature search 
A comprehensive literature search was undertaken to identify evidence in the English language 
that is:  
 of the highest quality available, considering the hierarchy of evidence ; 
 applicable to the UK, from world-wide studies;   
 of high methodological quality, as assessed by critical appraisal;  
 publicly available, including trials in press (“academic in confidence”).  
 
The following study designs were included:   
 systematic reviews, guidelines, randomised controlled trials (RCTs); controlled trials;  
[Systematic reviews and guidelines were identified and 'unpicked' for relevant studies to 
avoid any risk of double-counting.] 
 controlled before and after studies, interrupted time series and uncontrolled before and 
after studies were considered for potential relevance, especially where evidence from 
controlled trials was limited.  
 
2.1.1 Electronic sources (databases and websites) 
The following sources were searched in August 2011 to identify relevant evidence/studies 
in the English language published between 1990 and 2011.  In November 2011, update 
searches were conducted in the databases marked * and Globalink and ASH Scotland 
newsletters were checked on a weekly basis for additional research. 
The search strategy was developed for Ovid Medline [Appendix C] and translated for use in 
all other sources detailed below.  A full set of search strategies are available from the 
authors. 
Databases: 
• AMED (Allied and Complementary Medicine)* 
• ASSIA (Applied Social Science Index and Abstracts) 
• British Nursing Index 
• CINAHL (Cumulative Index of Nursing and Allied Health Literature) 
• Cochrane Central Register of Controlled Trials* 
• Cochrane Database of Systematic Reviews* 
• Cochrane Public Health Group Specialized Register [based at SURE] 
• Database of Abstracts of Reviews of Effectiveness (DARE)* 
• Database of promoting health effectiveness reviews (DoPHER), EPPI-Centre 
• Current Contents 
• EMBASE* 
• HMIC (or King’s Fund catalogue and DH data)* 
• Medline and Medline in Process* 
• UK Clinical Research Network Portfolio Database 
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• PsycINFO* 
• Sociological Abstracts 
• Social Policy and Practice 
• Web of Knowledge (Science and Social Science Citation Indexes)* 
• WHO Tobacco Control Database 
Web sites: 
• Smoke free  http://smokefree.nhs.uk    
• NHS Centre for Smoking Cessation and Training http://www.ncsct.co.uk/   
• Action on Smoking and Health (ASH) http://www.ash.org.uk     
• Treat tobacco.net  http://www.treatobacco.net/en/index.php   
• Society for Research on Nicotine and Tobacco  http://www.srnt.org    
• International Union against Cancer  http://www.uicc.org  
• WHO Tobacco Free Initiative (TIF)  http://www.who.int/tobacco/en   
• International Tobacco Control Policy Evaluation Project  http://www.itcproject.org   
• Tobacco Harm Reduction  http://www.tobaccoharmreduction.org/index.htm   
• Current controlled trials www.controlled-trials.com   
• Association for the treatment of tobacco use and dependence (ATTUD) 
http://www.attud.org  
• National Institute on drug abuse- the science of drug abuse and addiction  
http://www.nida.nih.gov/nidahome.html  
• NICE  http://www.nice.org.uk/ 
• OpenGrey http://www.opengrey.eu/  
• Public health observatories http://www.apho.org.uk/  
• Scottish Government http://home.scotland.gov.uk/home  
• Welsh Government http://wales.gov.uk/?lang=en  
• NHS Evidence  http://www.evidence.nhs.uk/  
• Joseph Rowntree Foundation http://www.jrf.org.uk/  
• The Centre for Tobacco Control Research (University of Stirling) 
http://www.management.stir.ac.uk/research  
• UK Centre for Tobacco Control Studies http://www.ukctcs.org/ukctcs/index.aspx  
• Tobacco Control Research Group (University of Bath) 
http://www.bath.ac.uk/health/tobacco/   
• Health Evidence Canada http://health-evidence.ca/articles/search   
• ASH Scotland news digest http://www.ashscotland.org.uk/ash/4782    
• American Association of Public Health Physicians http://www.aaphp.org/tobacco  
• Health NZ News  http://www.healthnz.co.nz/News2010.htm  
• Globallink  http://www.globalink.org    
• Cancer Research UK http://www.cancerresearchuk.org  
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2.1.2 Additional searches 
Following database and web site searching, the contents pages of the ‘top’ journals (ie the 
journals that contain the greatest number of papers that meet inclusion criteria) were hand 
searched – Addiction, Nicotine & Tobacco Research and Preventive Medicine - for the 
previous twelve months.  Citation searches via Web of Science were also carried out for 
included papers. 
NICE issued a call for evidence from registered stakeholders in August 2011. 
In addition, first authors of all the studies that met the inclusion criteria and other topic 
specialists identified by the Expert Advisory Group and NICE were contacted to request 
information on additional published studies, unpublished work or research in progress.   
Information on studies in progress, unpublished research or research reported in the grey 
literature was sought through searching a range of relevant databases including OpenGrey, 
Conference Proceedings Citation Index: Science (Thompson Reuters), Inside Conferences, 
National Technical Information Service (NTIS) and Clinical Trials.gov 
Results of the literature searches were imported into Reference Manager and de-
duplicated. 
2.2   Inclusion/Exclusion criteria: 
 Inclusion Exclusion 
Population People of all ages who: 
 are not willing or able to quit, but 
want to reduce smoking. (ie, reduce 
the harm that smoking is doing to 
their health or the health of those 
around them); 
 want to quit smoking but are not 
willing or able to stop using nicotine  
and who take part in a study 
examining a tobacco harm reduction 
approach; 
 want to stop smoking temporarily, 
for example, while at work or for 
surgery; 
 participate in interventions designed 
to reduce the number of cigarettes 
smoked per day; 
 participate in pre-operative  
interventions designed to ensure 
abstinence on day of operation. 
With a particular focus on those who 
Pregnant women 
[but the post partum population 
was included] 
Interventions to reduce the 
effects of second hand smoke on 
children where it is not possible 
to determine the effect on the 
parents' cigarette consumption 
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have been identified as:  
 at increased health risk from smoking, 
 from more disadvantaged groups and, 
thus, vulnerable to health 
inequalities.   
Interventions  Pharmacotherapies that are licensed 
for cutting down, temporary 
abstinence or harm reduction:  
o All nicotine replacement therapy 
(NRT) products (gum, transdermal 
patches, inhalers, microtabs, 
mouth/nasal sprays and lozenges2) 
 Other non-tobacco ‘nicotine-
containing products’, such as 
‘electronic nicotine delivery systems’ 
(sometimes known as ‘electronic 
cigarettes’ or ‘e-cigarettes’) and 
topical gels.  
 Behavioural support, counselling or 
advice for individuals/groups. 
 Self help. 
 
 Pharmacotherapies that are 
not licensed for cutting down, 
temporary abstinence or harm 
reduction; including nicotine 
agonists (eg varenicline) and 
antidepressants (eg 
bupropion).  
 Any products containing 
tobacco. This includes products 
that claim to deliver reduced 
levels of toxicity (such as 'low 
tar' cigarettes), or that reduce 
exposure to tobacco smoke, for 
example, by warming instead 
of burning it.  
 Products that are smoked that 
do not contain tobacco, such as 
herbal cigarettes.  
 Smokeless tobacco products 
such as gutka, or paan.  
 ‘Snus’ or similar oral snuff 
products as defined in the 
European Union’s Tobacco 
Product Directive (European 
Parliament and the Council of 
the European Union 2001).  
 Alternative or complementary 
therapies, such as 
hypnotherapy or acupuncture.  
Comparison All comparators  
Outcomes All types of outcomes (validated and 
unvalidated)  
 
 
                                                          
2
 Nicotine replacement therapy preparations are licensed for adults and children over 12 years, with the exception of Nicotinell® 
lozenges which are licensed for children under 18 years only when recommended by a doctor (BNF accessed online 28 July 2011) 
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Where interventions of interest were compared to/used in combination with excluded 
interventions, studies were included if the data for the interventions of interest could be 
disaggregated. Where disaggregation was not possible they were excluded. 
Studies that were designed as smoking cessation interventions were excluded, as were 
interventions designed to reduce the effects of second hand smoke on children where it is not 
possible to determine that parents were reducing their overall cigarette consumption. 
2.3 Study selection 
Titles and abstracts were screened independently by two reviewers using the inclusion/exclusion 
parameters. Any disagreement was resolved by discussion with a third reviewer and, if in doubt, 
included. Full paper screening was also undertaken independently by two reviewers, with 
recourse to a third to resolve any disagreements. Inter-rater reliability testing produced a Kappa 
score of 0.79.  
During the screening process records were tagged for relevance to specific questions and 
populations of interest. Final inclusion was agreed by the review team. Excluded papers were 
retained with reasons for exclusion.  Papers of potential relevance to review teams undertaking 
associated reviews were identified and forwarded to those teams.  
2.4  Quality assessment  
Quality assessment was conducted using the GATE checklist for quantitative studies [NICE 2009]. 
Studies were assessed by one reviewer and checked by a second. Twenty percent of papers were 
assessed independently in duplicate. Any disagreement was resolved by discussion. The review 
team assessed each study’s internal and external validity; where external validity measured how 
far the findings of the study might be generalised beyond the participants to a wider population 
from which the participants were drawn (eg from one community setting in the US to all US 
communities) but not to other populations. These ratings are included in the evidence tables.  In 
addition, Appendix B provides a summary of the quality ratings for each element of the included 
studies that was assessed. Where randomisation methods were unclear or methodologically 
insufficient, the study is described as quasi-randomised. Inter-rater reliability scores were 
explored and resulted in an overall kappa score of 0.72. 
2.5  Applicability to the UK 
Based on advice from members of the Expert Advisory Group, it was agreed that research from 
settings where the smoking reduction programmes are sufficiently similar to those in the UK 
(including Spain, Norway, Denmark, Australia and New Zealand) would be assessed as having high 
applicability to the UK. 
2.6  Data extraction 
Data were extracted as specified in Appendix K of the NICE Public Health Methods Manual and are 
presented in the Evidence Tables with study characteristics, quality scores and outcome measures 
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reported by the authors (with associated 95% confidence intervals (CI) and p-values where 
available). 
2.7 Data synthesis 
The key findings of evidence have been summarised in concise narrative summaries and evidence 
statements and are supported by evidence tables (Appendix A).  The statements indicate:  
 the message given by the evidence; 
 the strength of the evidence (based on a quality assessment of the source studies); 
 the applicability of the results to the UK. 
A meta-analysis was conducted if at least two studies were sufficiently homogeneous in design 
and the intervention under investigation. Similarity between study design and interventions was 
explored using sub-group analyses. Treatment estimate and precision were used to determine if 
studies and interventions were suitable for pooling. Both clinical and statistical heterogeneity 
were assessed using the I² statistic. (Higgins 2011). Where heterogeneity was found to be at least 
moderate to substantial (I² > 50%) the clinical characteristics of the studies were examined to 
explore the cause of the heterogeneity. In the presence of substantial heterogeneity (I² > 60%) 
the cause was excluded in an additional sensitivity analysis.  
For dichotomous outcomes, meta-analyses data were presented as relative risk ratios (RR) and 
continuous outcomes as mean difference. The dichotomous outcomes that were found to exhibit 
statistical evidence of an effect, were used to calculate the number of participants needed to 
treat to report at least one positive outcome (NNT, assuming the control arms were indicative of 
the underlying population prevalence.  Meta-analyses were conducted using random effects 
models and all summarised data were provided with associated 95% CI.  
The strength of evidence assessment in the evidence statements is based on the most recent 
GRADE guidance (Guyatt 2010).  The definitions used are broadly defined as follows with potential 
for moving up or down a grade as summarised in the guidance (Guyatt 2010): 
GRADE low, very low quality  = weak evidence (eg before and after studies graded –) 
GRADE moderate quality  = moderate evidence (eg RCTs/quasi RCTs graded +) 
GRADE high quality   = strong evidence (eg RCTs graded ++) 
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3.  RESULTS 
3.1 Search Results 
The search strategy identified 9750 citations of which 9271 were excluded at title and abstract. Of 
the remaining papers to be considered in full text, 19 were unavailable, 70 were found to be 
clearly irrelevant and 46 were systematic reviews. Update searches identified an additional 30 
papers; giving a total of 376 papers which were considered for inclusion in one or more of the 
three reviews.  Two hundred and thirty six papers were considered for this review, of which 62 
were included. These comprised 46 studies and one systematic review (the latter included four of 
the 62 identified papers). A full list of excluded papers with reasons for exclusion is provided in 
Appendix G 
 
 
A brief summary of each of the included studies is provided in Table 1 and Appendix A.  
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3.2 Quality and applicability of studies 
The quality of the included studies was variable although there was a good body of consistent 
evidence in some areas and five of the included studies, all RCTS, were deemed to be of high 
quality (Bolliger 2000 ++, Chan 2011 ++, Glasgow 2009 ++, Hovell 2000 ++, Warner 2005 ++). Of 
the remaining studies there were 2 RCTs, 5 partial RCTs, 17 quasi-RCTs (unclear allocation 
concealment), 3 non RCTs, 2 controlled before and after (CBA) studies, 10 uncontrolled before 
and after (UBA) studies and 1 secondary analysis. The UBAs and secondary analysis were all 
considered to be of low quality. 
Five studies were carried out in the UK (Foulds 1992 +, Gray 2005 −, Irvine 1999 +, McCambridge 
2005 +, Munday 1993 −, Walker 2009 −) and six in countries with similar smoking treatment 
programmes to the UK:  three in Australia (Borland 1999 +, Kelly 2006 +, Wakefield 2002 +), two 
in Denmark (Pisinger 2005 −, Wennike 2003 +) and one in Spain (Jimenez-Ruiz 2002 −).  23 of the 
remaining studies were based in the USA, of which 11 were community based and feasible in the 
UK. 
In general there was little information on specific socio-economic groups with only three studies 
looking at lower SES populations (Hovell 2000 ++, Kelly 2006 +, Wakefield 2002 +). 
See Table 1 and Appendix A for details of all the included studies.
3.3 Outcomes 
Data were extracted for all smoking-related outcomes. Reduction and abstinence data (both 
sustained and point prevalence) were extracted for all outcomes longer than six months from 
baseline, or the longest available period if these data were not available. Both self-report and 
verified reduction/abstinence - carbon-monoxide (CO) or cotinine - data were extracted. 
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Table 1: Brief summary of included studies  
* Studies are complex and this table can only give a flavour of each intervention. See Appendix A for more detailed summaries. 
Author and Year  Location and 
setting3  
Population 
 
Study outline Internal validity4 
Audrain McGovern 
2011 
Quasi-RCT 
USA + 
(adolescent 
medical sites) 
355 adolescents 
(aged 14-18)  
Attrition: 5.1% 
Motivational interviewing versus brief structured advice over 12 weeks 
for smoking behaviour change. 
Self reported cigarettes per day (CPD), quit attempts and cotinine-
validated 7 day abstinence to 24 weeks 
Participant motivations: Did not need to be interested in quitting 
+ Participation required written parental 
consent, two issues with fidelity of MI 
intervention, no allocation method 
reported, no power calc.  
Batra 2005 
Quasi-RCT 
Germany & 
Switzerland  ++ 
(medical centres) 
364 adults 
Attrition: 47% (I), 
62% (C) 
Ad lib nicotine gum (4 mg) versus placebo for up to 12 months with goal 
of smoking reduction. 
Smoking reduction ≥ 50%, CO verified, to 13 months. 
Participant motivations: Willing to change behaviour but not to quit. 
+ High attrition, desired sample size not 
achieved, no allocation method, 3/5 
authors from pharmaceutical co. 
Benowitz 1998 
Controlled study 
(cross over) 
USA − 
(clinical study 
centre) 
12 adult males 
Attrition: 8% 
Nicotine patches (up to 63 mg/d) on ad lib smoking over 5 d per dose. 
Cigarette consumption, plasma nicotine, blood carboxy-haemoglobin 
during treatment 
Participant motivations: No desire to quit smoking 
− Research ward study, no details of 
randomisation, no inclusion criteria, 5 day 
intervention periods only, no wash out, no 
power calc. 
Bolliger 2000 
RCT 
Switzerland + 
(hospital 
pulmonary clinics) 
400 adults 
Attrition: 22%  
Nicotine inhaler (10 mg+ 1 mg menthol) vs placebo inhaler at 6-12 
cartridges per day for 18 months – encouraged to decrease use at 4 mths. 
Smoking reduction ≥ 50% to 24 months, CO verified to 4 months. 
Participant motivations: Willing to reduce but unable/unwilling to stop 
immediately 
++ Baseline differences in % women, pharma 
funded and part authored (but double 
blind). 
Borland 1999 
Cluster Quasi-RCT 
Australia + 
(workplace) 
41 workplaces 
(736 adults)  
Attrition: not 
provided. 
Self help manual plus four one hour facilitated sessions (time frame 
unclear) versus self help manual only. 
Reduction in cigarette consumption, changes in workday CPD, urges to 
smoke, addiction level to 6 months. 
Participant motivations: No information but whole workforce recruited. 
+ Recruitment problems, low interest and 
adherence to facilitated sessions, self 
reported outcomes only. 
Carpenter 2004 
Quasi-RCT 
USA + 
(community based) 
616 adults 
Attrition: 6% 
Proactive reduction support plus nicotine gum (4mg) or patch (7, 14 or 21 
mg) vs motivational calls vs no treatment.  In intervention groups brief 
advice to quit plus NRT offer at 6 weeks. 
+ Free NRT may have encouraged false 
reporting, no biochemical verification, 
outcome assessment not blinded, no 
                                                          
3
 The symbols (++ + –) in this column refer to the external validity; where ++ indicates an intervention that is applicable to all members of the population for which the study was designed. As external 
validity decreases, it is measured by + and then –. 
4
 The symbols in this column provide a summary rating for quality; where ++ indicates that the study has been conducted so as to minimise risk of bias. As quality decreases/risk of bias increases, it is 
measured by + and then –.  
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CPD, 7-day point prevalent abstinence to 24 weeks. 
Participant motivations: Not currently interested in quitting 
power calc. 
Carpenter 2007 
Secondary analysis 
of UBA 
USA – 
(genetic testing) 
729 adults 
Attrition: 72.6% 
Testing for alpha-1-antitrypsin (AAT) deficiency followed by a 3-months 
post test questionnaire to assess smoking status. 
CPD, ≥50% CPD reduction, quit attempts and steps towards quitting at 3-
months. 
Participant motivations: Actively sought AAT testing 
– No control group, low response, self 
reported outcomes, not generalisable 
since so few with AAT deficiency, 
secondary analysis, motivations uncertain, 
no power calc. 
Chan 2011 
RCT 
China + 
(community-based)  
1154 adults 
Attrition: 22.4% 
(CO validation) 
Smoking reduction counselling plus NRT (gum or patch [no dosage 
information] with/without adherence advice) versus cessation advice, 
with self help quitting pamphlet to all participants. 
Smoking reduction ≥50% CPD, self reported and CO validated cessation, 
to 6 months.  
Participant motivations: Interested in reducing but no intention to quit in 
near future 
++ Large difference between self reported 
and CO validated outcomes,  Groups 
with/without adherence advice merged, 
high % male vs female, high attrition re CO 
validation despite payment offered 
Cunningham 2006 
Quasi-RCT 
Canada  + 
(community-based) 
54 adults 
Attrition: 20% 
Safer smoking tips versus requests (control group) to share harm 
reduction activities. 
CPD, type of cigarette and quit attempts to 3 months. 
Participant motivations: 81% reported at least one serious quit attempt 
+ No biochemical validation, compensatory 
smoking a possibility, small sample size, 
high attrition, no power calc. 
Davis 2011 
Quasi RCT 
USA – 
(lab based GP visit 
simulation) 
218 adults 
Attrition: 44% 
15 min motivational interviewing vs prescriptive interview. 
Smoking reduction ≥50% CPD and abstinence (both cotinine verified), 
intentions to quit or reduce, to 6 months.  
Participant motivations:  Not ready to quit. 
+ High attrition  
Etter 2007 
RCT 
Switzerland ++ 
(community-based) 
923 adults 
Attrition: 8% (2y); 
27% (5y) 
Choice of NRT versus placebo versus no intervention.  All received an 
educational booklet. 
Smoking reduction ≥50% CPD, CPD, depth of smoking to 5 years. 
Participant motivations: No intention to quit during next 6 months 
 
+ No biochemical validation (but deliberate 
to limit attrition), some pharmaceutical 
funding to authors, no power calc.  
Fagerstrom 1997 
Partial RCT 
Sweden + 
(community-based) 
170 adults 
Attrition: 16% 
Familiarisation with NRT medications (2mg gum, 2mg tablet, patch, 
vaporiser or nasal spray [no dosage info]) followed by 2 weeks own 
choice, and 2 weeks randomised to specific medication. 
CPD, CO, cotinine, withdrawal score, views, adverse effects over 5 weeks. 
Participant motivations: Did not want to or could not give up smoking 
– No control, large reduction in run in week, 
results from groups merged, no wash out 
period, no power calc. 
Fossum 2004 
CBA 
Sweden + 
(child health 
centres) 
37 child health 
nurses  (41 
mothers) 
Training of child health nurses via ‘smoke free children’ versus no 
training. 
Maternal CPD verified by cotinine to 3 months. 
– Small sample, potential selection bias, two 
control groups and unclear how matched, 
no information on counselling 
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Attrition: 27% 
(mothers) 
Participants motivations:  No information content/duration, No ITT, discrepancy in 
control numbers reported in table/text, 
no power calc.  
Foulds 1992 
Quasi-RCT 
UK – 
(research centre) 
34 adults 
Attrition: 11.8% 
One week baseline, followed by week each of nicotine (15 mg) patches 
crossed over to placebo patches 
Nicotine placebo CO difference, CPD, plasma nicotine, cotinine, 
thiocyanate, subjective views, side effects 
Participant motivations: No information 
+ Normal cues not likely to be present in 
lab, small trial, no information on 
participant recruitment/motivation, no 
allocation information 
Glasgow 2009 
RCT 
USA ++ 
(community-based) 
320 adults 
Attrition: 37% (I), 
18% (C) 
Telephone counselling and tailored newsletters versus enhanced usual 
care over 6 months. 
Smoking reduction ≥50% CPD, CO validated and abstinence to 12 months 
Participant motivations: Not interested in quitting 
++ Exclusion of Spanish speaking smokers, 
high attrition, single setting only (Kaiser 
Permanente Colorado), no power calc. 
Gray 2005 
CBA 
UK + 
(community-based) 
162 adolescents 
Attrition: 13% 
Single motivational interview versus no intervention. 
Smoking prevalence, cigarettes per week, cut down/quit attempts self-
reported at 3 months 
Participant motivations: No information 
– Self reported data only, non equivalent 
groups, little information and potential 
variation in delivery of MI, motivations 
of participants and researchers 
unknown, no power calc. 
Griffiths 2010 
UBA 
Canada – 
(community-based) 
56 adults with 
severe & 
persistent mental 
illness 
Attrition: 39% 
12 weeks counselling sessions (Tobacco Addiction Recovery Programme). 
CPD, tobacco dependence, use of NRT at end of intervention 
Participant motivations: No information 
– Self reported data only, no control, small 
sample, no follow up period, no ITT, no 
power calc. 
Gulliver 2008 
Quasi-RCT 
USA + 
(community-based) 
208 military 
veterans 
Attrition: 60.2% 
Single motivational interview plus deep breathing versus MI plus 
incentive spirometer versus MI alone. 
Abstinence verified by CO, CPD to 6 months 
Participant motivations: Had not presented for smoking cessation or 
expressed any motivation to quit. 
+ No (non MI) control, unknown therapist 
adherence to MI procedures, participant 
adherence to techniques unknown, 
almost entirely male population, high 
attrition at 6 months, no allocation 
information,  
Hanson 2008 
Quasi-RCT 
USA ++ 
(high schools) 
 
103 adolescents 
Attrition: 28.7% 
NRT patch (up to 14 mg) or NRT gum (multiples of 2 mg) versus control 
(400 mg folic acid), plus weekly meetings for all participants for 4 weeks. 
CPD, expired CO, urinary cotinine to 6 months. 
Participant motivations: Not interested in quitting. 
+ No placebo patch/gum, not blinded, high 
levels of co-morbidity in participants, 
(authors concerned that smoking 
reduction programme may give wrong 
message re health effects of smoking), no 
power calc. 
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Hatsukami 2005 
Quasi-RCT 
USA + 
(community-based) 
151 adults 
Attrition: 35.1% 
(12 weeks) 
6 week planned reduction schedule plus gum (4 mg) versus wait list 
control. 
Blood measures including cotinine, CPD, abstinence, respiratory 
symptoms to 26 weeks. 
Participant motivations: Interested in reducing but not quitting. 
– Short time scale, results for intervention 
and wait list controls merged, high 
attrition over short period, no power 
calc.  
Hatsukami 2007 
UBA 
USA – 
(community-based) 
64 adults 
Attrition: 69% 
Escalation, de-escalation of NRT patch (45 mg max.) over 7 weeks 
CPD, CO, urinary cotinine, withdrawal, physiological measures to 7 weeks. 
Participant motivations: Not immediately interested in quitting. 
– No placebo control, some variations in 
way patches applied, no ITT, no post 
treatment follow up, no power calc. 
Horn 2007 
RCT 
USA ++ 
(emergency 
department) 
75 adolescents 
Attrition: 65% 
Motivational intervention over 6 months plus workbook versus standard 
care with quit advice. 
Self reported CPD, abstinence to 6 months. 
Participant motivations: No information. 
+ Recruitment difficulties, largely white 
sample, high attrition, no power calc. 
Hovell 2000 
RCT 
USA ++ 
(community-based) 
108 low income 
mothers 
Attrition: 11% 
Individualised counselling over 3 months to reduce young children’s 
exposure to environmental tobacco smoke versus nutritional counselling 
and brief smoking advice. 
CPD, cotinine verified, and abstinence to 12 months from baseline. 
Participant motivations: No information. 
++ No limitations identified. 
Hurt 2000 
UBA 
USA – 
(community-based) 
23 heavy smokers 
Attrition: 30% 
12 weeks behavioural counselling for scheduled reduction with NRT 
inhaler (up to 16 per day; 5 mg per cartridge). 
CPD, CO, cotinine, withdrawal symptoms, inhaler usage to 24 weeks. 
Participant motivations: Wanted to reduce but not stop smoking. 
– Very small sample, no control group, no 
power calc. 
Irvine 1999 
Quasi-RCT 
UK ++ 
(community-based) 
501 families with 
an asthmatic child 
Attrition: 13.2% 
Advice on passive smoking and asthma and reducing child’s exposure plus 
commercial leaflet on smoking versus commercial leaflet only. 
CPD (parents), [also children’s cotinine levels] at 12 months. 
Participant motivations: No information 
+ No ITT, concerns that study was 
underpowered (though power calc. for 
primary outcome of child cotinine 
reported) 
Jimenez-Ruiz 2002  
UBA 
Spain + 
(smokers’ clinic) 
17 adults with 
severe COPD 
Attrition: None 
Nicotine gum (4 mg) for ad libitum use to 18 months. 
CPD, nicotine use, spirometric tests, CO, adverse events to 18 months. 
Participant motivations: Unable to quit. 
– Very small uncontrolled study, no power 
calc. 
Joseph 2008 
RCT 
USA + 
(community-based) 
152 adults with 
cardiovascular 
disorder 
Attrition: 31.5 – 
35.9% (18 mths) 
Smoking reduction counselling with nicotine gum (4 mg) over 18 months. 
CPD, abstinence, CO, cotinine,other biomarkers, heart disease symptoms, 
QoL, walk test, adverse events to 18 months. 
Participant motivations:  Unwilling and uninterested in setting a quit date 
over next 30 days. 
 
 
+ Sub-optimal power for some outcomes, 
mainly male heavily dependent smokers 
limit generalisability, reduction not CO 
verified, assessment unblinded 
THR 3.3 Review 3 - Effectiveness of tobacco harm reduction approaches without the prior intention of quitting with and without 
assistance 
 
 
 
32  
 
Kelly 2006 
Quasi-RCT 
Australia ++ 
(high schools) 
56 adolescents 
from lower SES 
families 
Attrition: 25% 
Single motivational interview versus standard advice. 
Self reported days per week smoking, CPD, smoking refusal self efficacy at 
6 months. 
Participant motivations: No information. 
+ Small sample, self reported data, high 
attrition, no allocation information, no 
power calc. 
Kralikova 2009 
Quasi-RCT 
Czech Republic + 
(medical centres) 
314 adults 
Attrition: 38.9% 
Nicotine gum (4 mg) or inhaler (10 mg) versus placebo for 6 months plus 
3 months voluntary tapering. 
Smoking reduction ≥ 50%, short-term and sustained abstinence verified 
by CO, intention to quit, adverse events to 12 months. 
Participant motivations: Wanted to reduce smoking and had made ≥ 1 
quit attempts but did not need to be motivated to quit. 
+ Some reduction between screening and 
baseline visits, significant attrition 
McCambridge 2005 
RCT 
UK ++ 
(further education 
colleges) 
200 young people 
Attrition: 19% 
Single motivational interview versus education as usual. 
CPD, other drug and alcohol use, health problems, behaviours and 
attitudes to drugs, state of change at 12 months. 
Participant motivations: No information. 
+ No, no intervention, control; No 
biochemical validation of outcomes. 
Munday 1993 
Non-RCT 
UK + 
(teaching hospital) 
233 patients 
awaiting surgery 
Attrition: unclear 
Leaflet advising ≥ 6 weeks pre-surgery cessation versus no advice. 
Pre-operative abstinence for ≥3 days, CPD at surgical admission. 
Participant motivations: No information 
– When receiving the leaflet patients did 
not know date of surgery, may not have 
understood leaflet, outcomes self 
reported, no randomisation, little 
baseline information, no power calc. 
Pickworth 1994 
UBA 
USA  – 
(residential 
research ward) 
10 adults 
Attrition: None 
Escalating nicotine patches (up to 44 mg) for 7 days periods in random 
double blind order plus ad lib smoking during 30 day stay. 
CPD, CO, puff measure, plasma cotinine and nicotine. 
Participant motivations: No current interest in quitting. 
– Close involvement of pharmaceutical 
company, uncontrolled study in tiny 
population group (some with extensive 
drug abuse history), no power calc. 
Pissinger 2005  
Partial 
RCT/secondary 
analysis 
Denmark + 
(community-based) 
39 adults 
Attrition: 51.3% 
overall for 
intervention 
group 
Subgroup receiving lifestyle consultation and 6 smoking reduction group 
sessions over 6 months versus no intervention 
CO to 6 months. 
Participant motivations: Unable or unwilling to quit. 
– No biochemical validation, poor 
compliance with smoking reduction 
groups, lack of clarity since appears to be 
a predominantly smoking cessation 
intervention, some baseline differences, 
no power calc. 
Polosa 2011 
UBA 
Italy – 
(hospital) 
40 hospital staff 
Attrition: 32.5% 
E-cigarette kit and maximum of 4 cartridges per day to 24 weeks. 
Product use, ≥50% CPD reduction, CO, adverse events to 24 weeks. 
Participant motivations: Not wishing to quit. 
– Small uncontrolled study, high attrition, 
lead author is consultant for e-cigarette 
supplier 
Rennard 1990 
UBA 
USA – 
(setting unclear) 
15 adult heavy 
smokers 
Attrition: None 
≥ 20mg nicotine gum daily and payment to 2 months; subjects agreed to 
reduce CPD by ≥ 50%. 
CPD, CO, respiratory tract inflammation. 
– Study not designed as an efficacy study 
but to examine respiratory tract effects, 
no control group, short term follow up, 
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Participant motivations: Not currently interested in quitting. small population and no description, 
pharma company funding, no power 
calc. 
Rennard 2006 
Quasi-RCT 
USA + 
(community-based) 
429 adults 
Attrition: 64% 
Nicotine (10 mg) versus placebo inhaler with instruction to reduce 
smoking as much as possible; smoking cessation recommended at mth 6. 
≥50% CPD reduction & abstinence, verified by CO, intentions to quit, QoL, 
cardiovascular risk markers, adverse events to 15 months. 
Participant motivations: Wanted to reduce but unwilling to quit. 
+ High attrition, no information on study 
funding (and four authors employees for 
pharma company) 
Riggs 2001 
Quasi-RCT 
USA + 
(community-based) 
20 adult 
volunteers 
Attrition: unclear 
One week hierarchical reduction (easiest cigarettes first) versus one week 
increased inter-cigarette interval in cross over design, with ad lib nicotine 
gum (2 or 4 mg). 
CPD, CO, salivary thiocyanate, ease of reduction, adverse events to end of 
treatment 
Participant motivations: Not currently interested in quitting but wishing 
to reduce. 
– Small self selected sample, short 
duration, no follow up, CO measures not 
linked to CPD 
Riley 2002 
Quasi-RT 
USA ++ 
(community-based) 
93 adults 
Attrition:32% 
(CSGR) 45% (SER) 
Computerised scheduled gradual reduction (CSGR) versus selective 
elimination reduction (SER) to 5 weeks. 
≥50% CPD reduction, abstinence validated by CO to 12 months. 
Participant motivations: 
+ Smoking rates by self report only, lack of 
no treatment control, high attrition, no 
allocation method information, authors 
worked for organisation with commercial 
interest in CSR products, no power calc. 
Roll 1998 
UBA 
USA – 
(mental health 
setting) 
11 adults with 
schizophrenia/ 
Schizoaffective 
disorder 
Attrition: 9% 
Regular visits over 3 weeks with cash payments for smoking reduction – 
intensive during week 2. 
CO to 8 weeks post intervention. 
Participant motivations: Not considering quitting. 
– Short term, small scale, uncontrolled, no 
power calc. 
Schleicher 2010 
RCT 
USA + 
(university) 
58 students with 
elevated 
depressive 
symptoms 
Attrition: 39.7% 
6 cognitive behavioural sessions over 8 weeks for smoking change versus 
6 sessions to increase fruit/vegetable consumption. 
≥50% CPD reduction, abstinence, salivary cotinine (no results provided), 
motivation, psychological outcomes, product use to one month post 
intervention. 
Participant motivations: Not seeking treatment for smoking. 
+ Small scale pilot, short follow up, self 
report outcomes only, significant attrition 
(though ITT used) 
Thomsen 2010 
Systematic review 
World wide + 
(literature review) 
8 RCTs of smokers 
scheduled for 
elective surgery 
Attrition: N/A 
Any pre-operative brief or intensive intervention to assist abstinence at 
time of surgery. 
Abstinence at time of surgery and 12 months post-operatively. 
Participant motivations:  Unclear 
 Small sample sizes, various smoking 
policies introduced over period covered 
by studies, limited information on search 
strategy and motivations of participants. 
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Tidey 2002 
UBA 
USA – 
(outpatient mental 
health centre) 
14 adults with 
schizophrenia/ 
Schizoaffective 
disorder 
Attrition: 21.4% 
Contingency management (CM; cash payments) plus 21 mg nicotine 
patch for reduction versus CM plus placebo versus non contingency 
monetary reinforcement plus placebo; 5 day spells of treatment with 
washout weeks. 
CO, nicotine withdrawal scores, salivary cotinine, other drug use, adverse 
effects to 2 weeks post study. 
Participant motivations: Not actively trying to quit. 
– Author concerns that 21 mg patch not 
strong enough for this group, small 
sample size, no randomisation to 
treatments, no CPD reports 
Wakefield 2002 
Non-RCT 
Australia ++ 
(paediatric 
outpatients) 
292 families with 
child with asthma 
Attrition: 9.6% 
Formal letter providing child’s cotinine-to-creatinine ratio with minimally 
tailored feedback and booklets versus usual care. 
(Smoking ban in home), CPD, abstinence, (child’s cotinine, reduction in 
smoking in front of child, smoking ban in car) 
Participant motivations: No information but does not appear that parents 
needed to be motivated to quit. 
+ No randomisation, low power. 
Walker 2009 
UBA 
UK + 
(hospital) 
25 forefoot 
surgery patients 
Attrition: None 
Outline of risks and advice to stop smoking pre-surgery approx 6 months 
in advance of surgery. 
Reduction (not defined), abstinence at time and 12 months post surgery. 
Participant motivations: No information. 
– No biochemical validation, no control 
group, single surgeon’s intake only, small 
sample, no power calc. 
Warner 2005 
RCT 
USA + 
(surgical clinic) 
116 elective 
surgery patients 
Attrition: ca 15% 
NRT patch (21, 35 or 42 mg/d) on morning of surgery and 30 days post 
op. 
Self reported CPD and abstinence, nicotine withdrawal, psychological 
stress and pain, patch adherence to 6 months post op. 
Participant motivations: Mixed but more than 80% at action stage of 
change. 
++ Participants likely to be motivated, 
limited time for acclimatisation to patch 
pre surgery, high short term attrition 
Wennike 2003 
Quasi-RCT 
Denmark + 
(community-based) 
411 adults 
Attrition: Unclear 
but circa 59% 
Nicotine gum (2 or 4 mg) up to 12 months versus placebo gum. 
≥50% CPD reduction and abstinence, both CO verified, changes in 
attitudes to 24 months. 
Participant motivations: Wanted to reduce smoking with nicotine gum. 
+ High attrition rate 
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4. FINDINGS 
Q1. How effective are pharmacotherapies in helping people cut down or abstain from smoking, 
temporarily or indefinitely without the aim of quitting? 
Nicotine replacement therapy (NRT) products are the only pharmacotherapies with a UK 
marketing authorisation for cutting down, temporary abstinence or harm reduction.5 NRT is 
available in the following formulations: chewing gum, transdermal patches, inhalers, microtabs, 
mouth/nasal sprays and lozenges.  
Nine studies, one RCT (Bolliger 2000 ++), five quasi- RCTs (Batra 2005 +, Etter 2007 +, Kralikova 
2009 +, Rennard 2006 +, Wennike 2003 +) and three uncontrolled before and after designs 
(Hatsukami 2005 −, Jiménez-Ruiz 2002 −, Rennard 1990 −) explored the effect of NRT versus 
placebo on smoking reduction. One RCT (Warner 2005 ++) investigated NRT versus placebo on the 
effect of pre and post-operative smoking behaviour.  Five studies (Benowitz 1998 −, Fagerström 
1997 −, Foulds 1992 +, Hatsukami 2007 −, Pickworth 1994 −), of which only one was controlled 
(Foulds 1992 +), looked at the effect of nicotine on the suppression of ad libitum smoking. The 
latter are largely small exploratory studies with low quality ratings, and are considered at the end 
of this section. 
Six studies were conducted in the USA (Benowitz 1998 −, Hatsukami 2007 −, Pickworth 1994 −, 
Rennard 1990 −, Rennard 2006 +, Warner 2005 ++), three in Switzerland (Batra 2005 +, Bolliger 
2000 ++, Etter 2007 +) with Batra 2005 + also including populations from Germany, two in 
Sweden (Fagerström 1997 – and Kralikova 2009 +), one in Denmark (Wennike 2003 +) and one in 
the UK (Foulds 1992 +).  
Of the six studies discussed below that were rated as high or moderate quality (Bolliger 2000 ++, 
Rennard 2006 +, Batra 2005 +, Wennike 2003 +, Etter 2007 +, Kralikova 2009 +) all compared NRT 
with placebo. In all six studies any advice or information was provided to both NRT and placebo 
groups.  
Nine studies in which NRT was combined with a behavioural intervention are summarised in 
section 4.4 (Chan 2011 ++, Carpenter 2004 +, Hanson 2008 +, Joseph 2008 + Griffiths 2010 –, 
Hurt 2000 −, Pisinger 2005a −, Riggs 2001 –, Tidey 2002 –). 
NRT versus placebo for reduction 
Inhaler versus placebo 
One RCT (Bolliger 2000 ++) and one quasi RCT (Rennard 2006 +) looked the efficacy of NRT inhaler 
vesus placebo. Bollinger 2000 ++ examined the efficacy of 10mg nicotine/1mg menthol inhaler for 
long term reduction of smoking. The intervention group were instructed to use the inhaler as 
needed and recommended to use 6-12 cartridges over 24 hours and encouraged to decrease use 
of the inhaler after 4 months but continue treatment for 18 of the 24 months, participants in the 
placebo group received a matched placebo inhaler. All participants received information on the 
implications of smoking and its effects on health and were willing to reduce smoking but unable 
or unwilling to stop smoking immediately. A significantly greater sustained reduction in number of 
cigarettes smoked was observed for the intervention group versus the placebo group as verified 
                                                          
5
  Nicotine replacement therapy preparations are licensed for adults and children over 12 years, with the exception of Nicotinell® 
lozenges which are licensed for children under 18 years only when recommended by a doctor (BNF accessed online 28 July 2011) 
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by expired CO measurements at 4, 12 and 24 months, OR 3.55 (95% CI: 2.04, 6.19) p<0.001, 3.59 
(95% CI: 1.65, 7.80) p=0.002 and 3.39 (95% CI: 1.39, 8.29) p=0.012 respectively. Abstinence as 
verified by expired CO measurements was only significant at 4 months, ORs for 4, 12 and 24 
months: 3.41 (1.16, 10.01) p=0.044; 1.36 (0.63, 2.95) p=0.557; 1.26 (0.65, 2.47) p=0.609. A 
secondary analysis, (Bolliger 2002−), found that at 2 years successful reducers had a significantly 
greater decrease in plasma cotinine measurements than unsuccessful reducers (60% vs. 1%, 
p<0.001). Rennard 2006 + investigated the effect of an ad libitum 10 mg NRT inhaler versus 
placebo inhaler, plus reduction advice, on healthy adults within a 12 month intervention. At 12 
months the mean CPD reduction from baseline was 14.5 for the intervention and 12.6 for the 
placebo group.  Self reported results were validated by expired CO.  At 15 months point prevalent 
abstinence was 7.9% versus 1.4% (p=0.002). 
Gum versus placebo 
Two quasi-RCTs examined to efficacy of nicotine gum versus placebo, Batra 2005 + and Wennike 
2003 +. Batra 2005 + investigated the efficacy of 4mg of nicotine gum for reducing cigarette 
consumption among smokers not ready to quit but willing to change their behaviour. Participants 
were instructed to use gum on urge to smoke and to chew 6-12 pieces daily for up to 12 months, 
participants in the placebo group received matched placebo gum. They were all told to reduce 
smoking as much as possible. At the 13 month assessment 7.1% of the intervention group had a 
significant sustained reduction in cigarette consumption (≥50% reduction in CPD compared to 
baseline) versus 2.8% of the placebo group (p=0.088). At 13 months the 7-day point prevalence 
abstinence was 12% for the intervention group and 2.2% for the placebo group (p=0.015).  
Wennike 2003 + investigated the effect of 2mg and 4mg of nicotine gum for reducing cigarette 
consumption and smoking cessation in smokers not motivated or not able to quit smoking. Gum 
was provided for ad libitum use for up to 12 months. Participants in the placebo group received 
matched placebo gum. All participants received moderate behavioural smoking reduction 
information. Sustained smoking reduction (≥50% reduction in CPD compared to baseline) was 
significantly greater at all time points with active gum versus the placebo. 6.3% and 0.5% 
respectively, OR 13.9 (95% CI: 1.80, 107, p<0.001) at 24 months and 8.8% and 1.5% respectively, 
OR 6.51 (95% CI: 1.89, 22.5, p<0.001) at 12 months. Point prevalence cessation rates were 
significantly greater at all time points with active gum  versus placebo at 24 months,  9.3% and 
3.4% respectively, OR 2.90 (95% CI: 1.19, 7.07, p=0.015) and at 12 months, 11.2% and 3.9% 
respectively, OR 3.13 (95% CI: 1.36, 7.7, p=0.005). 
Self-reported reduction and abstinence were verified by expired CO measurement in both studies 
Three lower quality studies (effectively all UBAs) also explored the effect of NRT gum on reduction 
(Hatsukami 2005 −, Jiménez-Ruiz 2002 −, Rennard 1990 −). Hatsukami 2005 – was designed as a 
quasi RCT but the authors merged the study groups. Adult smokers were given 4 mg gum and 
reduction advice for a 6 week period. Those who found it difficult to achieve ≥ 50% reduction in 
CPD versus baseline goals were offered a 14 mg nicotine patch to be used with the gum. At 26 
weeks 27% achieved ≥ 40% reduction in CPD and 7% achieved cotinine verified abstinence. 
Jiménez-Ruiz 2002 – explored the effect of 4 mg nicotine gum and reduction advice in a UBA of 
heavy smokers (> 30 CPD) with severe chronic obstructive pulmonary disease.  At 18 months, the 
patients (29%; n=5) who had continued to use the gum had substantially reduced their CPD to 6±7 
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versus 39±11 at baseline.  The remaining patients (71%) had stopped using gum and relapsed to 
their baseline CPD levels. Rennard 1990 – examined the effect of ≥ 20 mg nicotine gum daily plus 
payment (amount unstated) and advice to reduce CPD by 50%, on healthy volunteers.  After 2 
months, self reported CPD decreased from 50.7±2.3 to 18.8±1.5 (p<0.001) and expired CO 
decreased from 48.5±2.5 to 27.3±2.5 ppm (p<0.001). 
Gum or inhaler versus placebo 
A quasi-RCT,(Kralikova 2009 +), evaluated the efficacy of 4mg nicotine gum or 10mg nicotine 
inhaler to aid smokers to reduce or quit smoking in a population of smokers who wanted to 
reduce smoking. Participants were recommended to use gum (maximum 24 pieces/day) or inhaler 
(6-12 cartridges not exceeding 12 in 24 hours,) ad libitum for 6 months followed by up to 3 
months voluntary tapering. Participants in the placebo group received a matched placebo 
product. All participants received brief behavioural smoking reduction/cessation information. 
There was no significant difference for smoking reduction between groups at 4 or 12 months 
follow-up. Significantly more smokers in the intervention group than in the placebo group had 
sustained abstinence at 12 months, 18.7% and 8.6% p=0.019.  
Gum, patch, inhaler or combination versus placebo and control 
A quasi-RCT, Etter 2007 +, looked at whether the reduction in cigarette consumption obtained 
after 6 months of NRT (choice of 15mg patch, 4mg gum, 10mg inhaler or combination)  was 
maintained 5 years after the end of treatment in smokers who were not motivated to quit. After 
testing samples of each product, participants ordered the amount and type of product they 
needed and received products by mail every other week for 6 months. Participants in the placebo 
group received matched placebo products. All participants received an educational booklet. At 
five years, reduction in CPD was similar for all 3 groups (NRT 7.9, placebo 6.6 and control 6.3) all 
p≥.43 (excludes quitters). The proportion of participants who had reduced their cigarette 
consumption by ≥50% compared with baseline was similar in all 3 groups (NRT 20.9%, placebo 
21.4% and control 18.3%) all p≥.48 (excludes quitters). Continuous abstinence rates (no smoking 
in previous 5 years) were also similar across groups (NRT 7.2%, placebo 6.3% and control 4.6%, 
drop-outs counted as smokers) all p>0.16. At two years, mean reduction in CPD was 9.8, 7.7 and 
7.7 in NRT, placebo and control groups respectively (all p ≤ .02). Overall, 31.3% in NRT group 
versus 21.9% in placebo (p=0.014) and 24.4% in control (p=0.052) had decreased CPD by at least 
50% compared with baseline. 
Examining NRT usage at 5 years showed  that fewer participants were using NRT than at 2 years 
but the same proportion of participants were using NRT across the groups (daily + occasional use 
NRT: Nicotine, 12%; placebo, 9%; no treatment, 11%; p =.48). NRT users were more likely to be 
current smokers (82%) rather than former smokers (18%). During the previous 30 days, former 
smokers had used NRT for longer (median=30 days) than current smokers (median=10 days) 
p=0.003. Former smokers using NRT daily (n=11) abstained from smoking before those not using 
NRT (n=109), median: 123 days versus 826 days, respectively, p=0.003. 
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Meta-analyses: NRT and reduction outcomes 
A series of meta-analyses were conducted to examine the effect of various forms of NRT on 
reduction outcomes. 
Figure 1.1 – Proportion of participants with ≥50% reduction in cigarettes per day 
Plot A – Analysis of all NRT studies versus placebo 
 
 
Plot B – Sensitivity analysis of NRT (without MI) versus placebo (excluding Chan 2011 ++) 
 
 
A meta-analysis of three RCTs and one quasi-RCTs (Bolliger 2000 ++, Chan 2011 ++, Etter 2007 +, 
Wennike 2003 +) examined the effect of NRT with or without MI on point prevalence reduction 
in CPD of at least 50% (Figure 1.1. Plot A).  As the Chan 2011 ++ intervention included a brief 
motivational component and could be considered clinically diverse, a sensitivity analysis was 
conducted from which that study was excluded (Figure 1.1, Plot B).   
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Results from both analyses show that NRT increases the chance of a participant achieving a point 
prevalence reduction in cigarette usage of ≥50%. The initial meta-analysis resulted in a relative 
risk (RR) = 1.46 (95% CI 1.20, 1.78; p=0.0002; I2=12%), with an NNT of 13 (95% CI 10, 20). The 
sensitivity analysis resulted in an RR=1.35 (95% CI 1.10, 1.65; p=0.004; I2=0%) and an NNT=17 
(95% CI 10, 50).  
Figure 1.2 –Cigarettes per day (% reduction from baseline) 
 
[Note: the axis on this Forest Plot is reversed in comparison with all other plots.] 
 
Three studies (one RCT and two quasi-RCTs) looked at the effect of NRT on percentage reduction 
in cigarettes per day from baseline (Bolliger 2000 ++, Batra 2005 +, Wennike 2003 +). The meta-
analysis found that CPD reduction as a percentage of baseline was greater when using NRT 
compared to placebo resulting in a risk difference (RD)  of -13.85 (95% CI: −25.25, −2.45; p=0.02; 
I2=40%).  
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Figure 1.3 – Participants with a sustained CPD reduction (any reduction compared to baseline) 
Plot A – All NRT studies versus placebo 
 
 
Plot B – Sensitivity analysis [excluding Kralikova 2009 +] 
 
 
Four studies (one RCT and three quasi-RCTs) investigating a variety of NRT methods versus 
placebo for any sustained CPD reduction compared with baseline (Bolliger 2000 ++, Batra 2005 
+, Kralikova 2009 +, Wennike 2003 +) were included in a meta-analysis (Figure 1.3, Plot A) with 
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an RR=2.45 (95% CI: 0.9, 6.4; p=0.07; I²=75%). However, severe statistical heterogeneity was 
found in this analysis. As outlined in the methods (see Section 2.7), the heterogeneity was 
investigated and was found to be due to a difference between Kralikova 2009 + and the other 
three studies. No clinical difference in study design was identified other than that Kralikova 
2009 + offered a choice of NRT delivery method. In a sensitivity analysis excluding this study 
(Figure 1.3 Plot B), NRT increased the chance of a sustained smoking reduction RR=3.38 (95% CI 
1.7, to 6.6; p=0.0004; I2=7%), with an NNT of 17 (95% CI 13, 34) and no evidence of statistical 
heterogeneity between studies.  
Meta-analyses: NRT and abstinence outcomes 
Further meta-analyses were conducted to examine the effect of various forms of NRT on 
abstinence outcomes. 
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Figure 1.4 – Smoking cessation by delivery mechanism (gum +/- inhaler, and inhaler). 
Plot A - Analysis of all NRT studies versus control  
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Figure 1.4 – Smoking cessation by delivery mechanism (gum +/- inhaler, and inhaler) 
PLOT B – Sensitivity analysis (NRT versus placebo only) 
 
 
A meta-analysis of nine studies – three RCTs and six quasi-RCTs − (Bolliger 2000 ++, Chan 2011 ++, 
Etter 2007 +, Batra 2005 +, Carpenter 2004 +, Joseph 2008 +, Kralikova 2009 +, Rennard 2006 +, 
Wennike 2003 +) was conducted to investigate whether NRT, with or without a behavioural 
intervention, versus control increased abstinence rates in smokers not looking to quit (Figure 1.4, 
Plot A). Additionally a sensitivity analysis was conducted excluding studies of NRT plus a 
behavioural intervention (Carpenter 2004, Chan 2011 ++, Joseph 2008 +) to examine differences 
(Figure 1.4, Plot B). 
The results indicate that NRT, with or without associated behavioural interventions, has a 
statistically significant effect on smoking cessation in study populations not looking to quit: 
RR=1.96 (95% CI 1.36, 2.80; p=0.0003; I²=56%) with an NNT of 20 (95% CI 13, 34). For the 
sensitivity analysis of NRT-only versus placebo the result was RR=1.93 (95%CI 1.26, 2.96; p=0.003; 
I2=54%), again with an NNT of 20 (95% CI 13, 34). 
NRT versus placebo in peri- and post-operative smoking behaviour 
An RCT (Warner 2005 ++) analysed the effects of nicotine patch versus placebo patch on self-
reported peri- and post-operative smoking behaviour in patients undergoing elective surgery with 
>80% of participants motivated to quit. Patients were provided with patches of 21, 35 or 42mg of 
nicotine/day (dose based on cigarette consumption) on the morning of surgery followed by a 30-
day post-operative supply. Across both groups 99% patients maintained abstinence during 
hospitalisation.  There was no significant difference between groups for continuous abstinence  at 
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30 days or 6 months post-operation, intervention=29% versus placebo=15% (p=0.66) and 
intervention=9% and placebo=15% (p=0.32), respectively. Smokers in the intervention group 30 
days post-operatively had significantly reduced the number of cigarettes smoked per day from 
baseline (mean ± SD: intervention = -9.7 ± 7.8, placebo = -6.1 ± 7.0, p=0.027) though this was not 
significant 6 months post-operation (mean ± SD: intervention = -5.0 ± 7.4, placebo = -5.3 ± 6.9, 
p=0.44).   
NRT effect on ad libitum cigarette smoking 
Five studies (Foulds 1992 +, Benowitz 1998 −, Fagerström 1997 −, Hatsukami 2007 −, Pickworth 
1994 −), of which only one was controlled (Foulds 1992 +), looked at the effect of nicotine on the 
suppression of ad libitum smoking.  
A quasi-RCT with a cross-over design (Foulds 1992 +) of one week nicotine patches (ca 15 mg 
released over 16h) and one week placebo patches suggested modest effects at most on CPD. The 
effect of the nicotine versus placebo patch on self-reported CPD over 6 days was not significant at 
-0.8 (95% CI -1.8 to 0.1). 
A very small UBA (Benowitz 1998 –) found transdermal nicotine patches (up to 63 mg) suppressed 
ad libitum smoking in a dose dependent manner. During the 5 day laboratory based study 
suppression of nicotine intake from smoking averaged 3% (95% CI, -37% to 43%), 10% (95% CI, -
31% to 50%) and 40% (95% CI, 6% to 74%) in the 21, 42 and 63mg conditions, respectively 
(p<0.05).  
Another UBA (Fagerström 1997 –) explored the effect of NRT, and choice of NRT, on cigarette 
consumption and motivation to quit. Researchers found that a range of NRT formulations (2mg 
gum, 2mg tablet, patch, vaporiser, nasal spray) supported CPD reductions.  Following a one week 
familiarisation period with the medications, subjects were randomised to a specific medication for 
two weeks, and then allowed free choice for two weeks. At 5 weeks, self reported CPD across all 
conditions declined from 22.6 (SD 7.0) to 10.4 (SD 1.0) (p<0.001); a 54% decrease, with the 
biggest drop (37%) during week 1. CO readings decreased from 22.7 (SD 8.5) to 14.8 (SD 8.4) ppm 
(p<0.001), confirming a 35% decrease in smoking. There was no significant effect between 
conditions on medication use. Cotinine levels remained steady, suggesting subjects were titrating 
nicotine to their original levels. 
Results from another UBA (Hatsukami 2007 –) suggested that escalating the dosage of an NRT 
patch up to 45 mg led to CO verified reductions in smoking. CPD from week 3 to 4 (15 to 30 mg 
NRT) reduced by 5.81 (p<0.0001). For CO, significant reductions were noted from weeks 3 to 4 
(15mg to 30 mg patch) (-3.36, p=0.0004) and weeks 4 to 5 (30 mg to 45 mg) (-3.25, p=0.0016). 
There was some evidence of greater inhalation per cigarette as CPD reduced. 
Finally a very small laboratory study (Pickworth 1994 –) in 10 subjects found that, compared to 
smoking rates in the placebo condition each of the nicotine conditions significantly reduced 
average CPD (placebo: 18.1±1, 22 mg: 15.3±1, 44 mg: 13.4±1). Significant reductions in expired CO 
were noted from the use of a 44 mg nicotine patch versus placebo, but not with a 22 mg patch. 
The nicotine content of the patch did not significantly affect the average or total puff duration on 
the daily cigarette. 
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Evidence Statements:  
1.1 There is strong to moderate evidence from nine studies - two RCTs, five quasi-RCTs 
and two UBAs - (Bolliger 2000 ++, Etter 2007 +, Batra 2005 +Hatsukami 2005 −, 
Jiménez-Ruiz 2002 −, Kralikova 2009 +, Rennard 1990 −, Rennard 2006 +, Wennike 
2003 +) that NRT (gum or inhaler) versus placebo is effective in reducing cigarette 
consumption across multiple outcome measures and in eventual abstinence in 
smokers not looking to quit.    
1.2  There is strong to moderate evidence from a meta-analysis of three RCTs and one 
quasi-RCT (Bolliger 2000 ++, Chan 2011 ++, Etter 2007 +, Wennike 2003 +) looking 
at ≥50% point prevalence reduction in CPD compared to baseline, that NRT, with or 
without a brief MI component, is more effective than placebo with a relative risk  
(RR) = 1.46 (95% CI 1.20, 1.78), with a number needed to treat (NNT) of 13 (95% CI 
10, 20). A sensitivity analysis excluding Chan 2011 ++ (which added a brief MI 
component to NRT) resulted in RR=1.35 (95% CI: 1.10, 1.65) and an NNT of 17 (95% 
CI 10, 50). Smoking reduction was verified by CO except in Etter 2007 +.  
1.3 There is moderate evidence from a meta-analysis of one RCT and 2 quasi-RCTs 
(Bolliger 2000 ++, Batra 2005 +, Wennike 2003 +) that NRT is more effective than 
placebo in percentage reduction in cigarettes per day from baseline with a risk 
difference (RD) of −13.85 (95% CI: −25.5, −2.45). 
1.4 There is unclear evidence from a meta-analysis of one RCT and three quasi-RCTs 
(Bolliger 2000 ++, Batra 2005 +, Kralikova 2009 +, Wennike 2003 +) for the efficacy 
of NRT for any sustained CPD reduction compared to baseline with an RR=2.45 
(95% CI: 0.9, 6.4). In a sensitivity analysis that excluded Kralikova 2009 + for 
significant heterogeneity, NRT increased the chance of a sustained smoking 
reduction RR=3.38 (95% CI 1.7, 6.6), with an NNT of 17 (95% CI 13, 34), and no 
evidence of between-study statistical heterogeneity.   
1.5 There is strong evidence from a meta-analysis of nine studies (three RCTs and six 
quasi RCTs) investigating cessation in populations not looking to quit (Bolliger 2000 
++, Chan 2011 ++, Etter 2007 +, Batra 2005 + , Carpenter 2004 +,  Joseph 2008 +, 
Kralikova 2009 +, Rennard 2006 +, Wennike 2003 +) that NRT with or without 
associated behavioural interventions has a statistically significant effect: RR=1.96 
(95% CI 1.36, 2.80) with an NNT of 20 (95% CI 13, 34). A sensitivity analysis 
excluding studies with a behavioural component (Carpenter 2004 +, Chan 2011 ++, 
Joseph 2008 +), found a similar result for NRT alone: RR=1.93 (95%CI 1.26, 2.96) 
and an NNT of 20 (95% CI 13, 34). 
 1.6 There is moderate evidence from one RCT (Warner 2005 ++) that nicotine patch 
versus  placebo is effective in reducing post-operative smoking consumption, a 
statistically significant self-reported reduction was observed 30 days post-operation 
but this was not maintained at 6 months. 
1.7 There is weak evidence from five studies (Benowitz 1998 −, Fagerström 1997 −, 
Foulds 1992 +, Hatsukami 2007 −, Pickworth 1994 −) that a nicotine patch may 
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help reduce ad libitum cigarette smoking. In the only controlled study (Foulds 1992 
+) the result was not statistically significant. 
The majority of the evidence is applicable to the UK as the studies are community based 
and feasible in UK settings, although Batra 2005 + involved participants making several 
clinic visits and  Foulds 1992 + was in a laboratory setting. Warner 2005 ++ was conducted 
within a specific population (patients undergoing elective surgery). 
 
Q2. How effective are different combinations of NRT products in helping people cut down or abstain 
from smoking, temporarily or indefinitely without the aim of quitting? 
No studies were found that looked at the efficacy of combinations of NRT products in helping 
people cut down or abstain from smoking without the intention of quitting. One quasi-RCT (Etter 
2007 +) permitted a combination of products but did not provide an analysis of take up or effects. 
Hatsukami 2005 –, a study designed as a quasi-RCT but which did not present results for 
participant groups separately, offered those who found it difficult to reduce CPD using gum, an 
additional 14mg patch. However data are not reported separately for this group. A UBA 
(Fagerström 1997 –) looked at the effect of choice of product on outcomes.   
Etter 2007 + explored whether a reduction in cigarette consumption obtained after 6 months of 
NRT (choice of 15mg patch, 4mg gum, 10mg inhaler or combination), was maintained 5 years 
after the end of treatment in smokers who were not motivated to quit. However a separate 
analysis of those participants using a combination of products was not conducted. 
Hatsukami 2005 − gave participants 4 mg gum and instructed them to reduce CPD from baseline 
levels to 75% in first 2 weeks, 50% in weeks 3-4 and 25% in weeks 5-6. Those who found it difficult 
to achieve 50% or 75% goals were offered 14mg nicotine patch to be used with gum. However, no 
separate data are provided for those who received the additional patch. Although designed as a 
quasi-RCT, the groups were merged. 
Fagerström 1997 – found that a range of NRT formulations (2mg gum, 2mg tablet, patch, 
vaporiser, nasal spray – doses not described) supported CPD reductions. Following a one week 
familiarisation period with the medications, subjects were randomised to a specific medication for 
two weeks, and then allowed free choice for two weeks. Authors reported (though little data in 
paper) that the overall effect of free choice on self-reported CPD reduction was 3.1 vs 1.1 
(p<0.001). For CO reduction the effect was 2.7 vs 0.9 ppm (p<0.05). The overall measures for 
cotinine were higher in the free choice than in the no choice groups (+1.6 vs -1.7 ng/ml) but the 
results were not significant. There was no significant effect between conditions on medication 
use. No clear medication preference emerged, though patch and vaporiser seemed not as good in 
reducing craving as gum and spray, and spray was rated as having the greatest “similarity to 
cigarettes”.  
Evidence Statement:  
2.1 No studies were found that looked at the efficacy of combinations of NRT products in 
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helping people cut down or abstain from smoking without the intention of quitting.   
 
Q3. How effective are ‘nicotine-containing products’ in helping people cut down or abstain from 
smoking, temporarily or indefinitely without the aim of quitting? 
For the purposes of this review ‘nicotine containing products’ were defined as ‘electronic nicotine 
delivery systems’ (sometimes known as ‘electronic cigarettes’ or ‘e-cigarettes’) and topical gels. 
Currently these products are not regulated by the Medicines and Healthcare products Regulatory 
Agency (MHRA). 
The only relevant intervention research identified was a proof of concept study designed as a 
UBA, (Polosa 2011−) where regular smokers of ≥ 15 factory-made CPD were provided with an e-
cigarette kit for ad libitum use, up to 4 cartridges per day. At 24 weeks follow up there was self-
reported 50% CPD reduction in 13/40 (32.5%) participants, with a reduction from a median of 25 
CPD (IQR 20, 30) to 6 CPD (IQR 5, 6) (p<0.001).  Results were validated by reduced CO levels. 
Product use varied greatly with a mean of 2.0 (±1.4) cartridges per day and a range of 0 to 4 per 
day over study period.  There was no relationship between cartridges per day and sustained 50% 
reduction or abstinence. 
Evidence Statement:  
3.1   Very weak evidence from one UBA (Polosa 2011−) suggests that e-cigarette availability 
can help smokers reduce their self reported CPD and CO levels.  
This evidence may be applicable to the UK as it is community based and feasible in a UK setting. 
 
Q4. How effective are behavioural support, counselling, advice or self-help (with or without 
pharmacotherapy) in helping people cut down or abstain from smoking, temporarily or 
indefinitely without the aim of quitting? 
Various types of behavioural support have been offered.  The most common approach was 
motivational interviewing (MI), which was used in nine studies (Chan 2011++, Audrain-McGovern 
2011 +, Carpenter 2004 +, Davis 2011 +, Gulliver 2008 +,Horn 2007 +, Kelly 2006 +, McCambridge 
2005 +, Gray 2005 −). Five of these studies were carried out among adolescents – three in healthy 
adolescents (Kelly 2006 +, Audrain-McGovern 2011 +, Horn 2007 +) and two in adolescent drug 
users (McCambridge 2005 +, Gray 2005 −). Of the remaining studies carried out among adults, 
three involved healthy adults (Chan 2011++, Carpenter 2004+, Davis 2011 +) and one was carried 
out among “psychiatrically complex” military veterans (Gulliver 2008 +).  Six studies were 
randomised controlled trials, five with randomisation at an individual level (Chan 2011 ++, 
Audrain-McGovern 2011 +, Davis 2011 +, Horn 2007 +, Kelly 2006 +) and one with randomisation 
clustered at the college level (McCambridge 2005 +). Two studies were quasi-randomised 
(Carpenter 2004+, Gulliver 2008 +), and one was a controlled before and after study (Gray 2005 
−). Two studies were carried out in the UK (McCambridge 2005 +, Gray 2005 −), five in the USA 
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(Audrain-McGovern 2011 +, Carpenter 2004+, Davis 2011 +, Gulliver 2008 +, Horn 2007 +), one in 
Australia (Kelly 2006 +), and one in China (Chan 2011 ++). 
Seven further behavioural studies utilised a range of techniques: one used cognitive behavioural 
therapy for college students with elevated depressive symptoms (Schleicher 2010 +); one 
explored the of effect intensive contingent positive reinforcement with cash payments for adults 
with schizophrenia (Roll 1998 – ); one examined the effectiveness of telephone counselling 
among adults scheduled for outpatient surgery or a diagnostic procedure (Glasgow 2009 +); one 
compared computer-aided reduction with manual-aided reduction among adults (Riley 2002 +); 
one examined the effectiveness of safer smoking tips for adults (Cunningham 2006 +); one looked 
at the effectiveness of workplace self-help programmes (Borland 1999 +); one investigated if 
knowledge of alpha-1-antitrypsin (AAT) deficiency is effective in influencing quit attempts and 
cigarette consumption (Carpenter 2007 –). Of these seven studies three were randomised 
controlled trials, two being individually randomised (Schleicher 2010 +, Glasgow 2009 +) and one 
being cluster randomised (Borland 1999 +). One study was a randomised non-controlled trial 
(Riley 2002 +), and one was a quasi-randomised controlled trial (Cunningham 2006 +).  Two 
studies were uncontrolled before and after studies (Roll 1998 –, Carpenter 2007 –).  
Five studies were carried out in the USA (Carpenter 2007 –, Glasgow 2009 +, Riley 2002 +, Roll 
1998 –, Schleicher 2010 +), one in Australia (Borland 1999 +) and one in Canada (Cunningham 
2006 +).  Two studies were specific to subjects with mental health conditions (Roll 1998 –, 
Schleicher 2010 +). 
Six studies examined behavioural therapy in combination with NRT. Hanson 2008 +, a randomised 
open-label trial, used cognitive behaviour therapy in combination with a nicotine patch or gum 
among adolescents.  Joseph 2008 +, a RCT; Hurt 2000 –, a UBA; and Pisinger 2005a –, a small sub-
group analysis of a RCT, combined counselling and behavioural strategies with nicotine 
replacement therapy for reduction among adults. Two studies examined behavioural support with 
NRT among adults with mental illness (Griffiths 2010 –, Tidey 2002 –). Hanson 2008 +, Hurt 2000 
–, Joseph 2008 + and Tidey 2002 – were conducted in the USA, Pisinger 2005a –, in Denmark and 
Griffiths 2010 – in Canada. 
One quasi -RCT in the USA compared NRT and hierarchical reduction versus NRT and increased 
inter-cigarette interval (Riggs 2001 –). 
One systematic review of RCTs (Thomsen 2010 +) which included trials from Denmark, Australia, 
Canada, Sweden and the UK, plus a controlled trial (Munday 1993−) and an uncontrolled before 
and after study (Walker 2009 −), both of which were conducted in the UK, reported on the 
effectiveness of pre-operative smoking cessation interventions.  All studies should be applicable in 
a UK setting. 
Motivational interviewing 
Nine studies were identified that described a ‘motivational interviewing’ component as part of 
the intervention. The fidelity of this MI component was examined using the definition outlined in 
Lai 2010; a Cochrane systematic review of motivational interviewing for smoking cessation. The 
review required the intervention to comply with the MI principles and practice of Miller and 
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Rollnick (Miller 2002). Specifically, the study should make specific reference to MI principles and 
some form of monitoring of MI should be reported. 
Six studies met Lai’s definition (Audrain McGovern 2011+, Davis 2011+, Gray 2005 −, Horn 2007 
+, Kelly 2006, McCambridge 2005). One (Gulliver 2008+) did not make any reference to 
monitoring. Two further studies combined a ‘motivational’ intervention with NRT (Carpenter 
2004+, Chan 2011 ++). Although both studies made reference to motivational interviewing 
techniques, neither described the nature of the intervention nor did they discuss monitoring; so 
did not meet either of the criteria outlined in Lai 2010. 
A brief summary of the MI interventions is provided below: 
Author Intervention Control group Intervention delivery 
Audrain McGovern 
2011 + 
Five intensive MI sessions - 
mix of 3 face-to-face (f2f) 
and 2 telephone interviews 
Five sessions of 
structured brief 
advice 
Trained counsellors 
Carpenter 2004 + 
[Note: fidelity to MI 
principles and practice 
unclear] 
Reduction aided by NRT      
(R-NRT): Three telephone 
calls focusing on 
behavioural reduction 
strategies. Plus NRT gum or 
patch for six weeks with 
additional NRT from week 6 
for those committing to 
quit. 
Motivational treatment 
(MT): Three telephone calls 
focusing on 5Rs, At week 6 
those committing to quit 
given NRT. 
No treatment University researchers 
Chan 2011 ++ 
[Note: fidelity to MI 
principles and practice 
unclear] 
A1: 3 x 15 mins face-to-face 
counselling on smoking 
reduction based on MI 
techniques and 3 x 3 mins 
adherence to NRT. Free 
NRT (choice of patch or 
gum – no dosage 
information). Plus self-help 
quitting pamphlet, ‘Tips for 
Quit Smoking’ 
A2: as above without 
adherence to NRT info 
Simple cessation 
advice at baseline. 
Plus self-help quitting 
pamphlet, ‘Tips for 
Quit Smoking’ 
 
Trained smoking 
cessation counsellors. 
Davis 2011 + 15-minute MI session Prescriptive interview University researchers 
trained MI deliverers 
but unclear who 
delivered. 
Gray 2005 − Single MI session Nothing Youth workers trained 
in MI 
Gulliver 2008 + 
[Note: authors do not 
state whether MI 
component was 
monitored for practice 
Single MI session 45-50 
minutes 
All three groups 
receive MI. One group 
also received 
instruction in deep 
Psychologists with ≥3 
years’ experience 
treating addictions and 
trained using 
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fidelity] breathing, instruction 
in how to use a 
spirometer 
Motivational 
Interviewing 
Professional Training 
Series. 
Horn 2007 + 15 to 30 minute patient-
tailored f2f motivational 
interview. 
Stage matched self-help, 
take home workbook with 
audio. 
Handwritten personal 
postcard within 3 days.   
 Follow-up “booster” phone 
calls at 1, 3, and 6 months.  
Standard care (brief 
advice) 
Researchers trained in 
MI 
Kelly 2006 + Single 60 minute f2f MI 
session 
Standard care Psychotherapist 
trained in MI 
McCambridge2005 + Single 60 minute f2f MI 
session 
Nothing Researcher trained in 
MI 
 
MI in adolescents 
Kelly 2006 + carried out a randomised controlled trial in which a motivational interviewing 
intervention was delivered to Australian adolescents caught smoking in high school.  Intervention 
participants received a one hour MI session with reading materials also being provided.  At three 
and six month follow-up there were no differences between the intervention and control groups 
in terms of number of smoking days and the number of cigarettes smoked on smoking days. 
Audrain-McGovern 2011 + evaluated the efficacy of motivational interviewing (MI) compared 
with structured brief advice (SBA) for adolescent smoking behaviour change.  In this randomised 
controlled trial intervention participants received three 45-minute office-based MI sessions and 
two 30-minute office or telephone sessions over 12 weeks.  The intervention was based on 
motivational enhancement therapy (MET), which adds personalized feedback about assessment 
results and collaborative development of a formal change plan to the standard principles and 
techniques of MI.  The control group received 5 sessions of structured brief advice, focusing on 
the “5 A’s” for those interested in quitting and the “5 R’s” for those not interested in quitting.  In 
each session, the 5 A’s/R’s were followed by a review of self-help materials, followed by a brief 
check-in to see if the adolescent needed help in gaining access to services.  Treatment group was 
not significantly associated with attempting to cut back at either week 12 or week 24 (both 
p>0.05), although adolescents who received MI showed a greater reduction in the number of 
cigarettes smoked daily than adolescents who received SBA (5.3 versus 3.3 fewer CPD 
respectively).  Those receiving MI were around 60% less likely than those who received SBA to try 
to quit smoking (OR=0 .41, 95% CI 0.17–0.97). 
In their randomised controlled trial, Horn 2007 + examined the efficacy of an emergency 
department based motivational teenage smoking intervention.  The intervention consisted of one 
15 to 30 minute patient-tailored face-to-face motivational interview including a readiness 
assessment, a reflection on smoking behaviours, and a health inventory.  Participants were also 
given a stage matched self-help take home workbook with audio, they received a handwritten 
personal postcard within three days of the emergency department visit, and also received three 
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follow-up booster phone calls at one, three and six months post emergency department visit.  
Control group participants received no more than two minutes of generic advice, referral to a 
telephone helpline, and one follow-up telephone call six months after the emergency department 
visit.  At the six month follow-up intervention participants showed a greater reduction in the 
number of cigarettes smoked than the control participants, although this difference was not 
significant (20.5% versus 6.1% reduced CPD compared to baseline; p=0.15).  Among teenagers 
who reduced their smoking, the intervention group reduced more than the control group at the 
six month follow-up, although again this difference was not significant.  There were also no 
differences in quit rates at six months between the two groups (2.5% versus 2.9%, p=0.55). 
MI in adolescent drug users 
McCambridge 2005 + carried out a cluster randomised controlled trial in which they assessed 
whether a single session of motivational interviewing, discussing alcohol tobacco, and illicit drug 
use, would lead to a reduction in use of these drugs or in perceptions of drug related risk and 
harm among young people who had current involvement with drug use. The intervention was 
adapted from the literature on MI and took the form of a topic-based 1 hour single session face-
to-face interview. Although the number of cigarettes smoked per week three months post-
intervention was lower in the intervention group than the control group (p=0.009), the 
differences between groups disappeared over time; being non-significant at 12 months (p>0.1).  
When restricting the analyses to only those who were smokers at study entry, the mean number 
of cigarettes smoked per week declined significantly in the intervention group (41.0 to 32.3, 
p=0.02), but not in the control group (41.0 to 38.9, p>0.01). At three month follow-up 25% of 
smokers at baseline in the intervention group quit compared to 8% in the control group (p=0.008).  
After adjusting for confounders though this result fell just short of significance (p=0.056).  Twelve 
month data were not reported for this outcome. 
Following on from this, Gray 2005 − undertook a controlled before and after study examining 
whether a single session of motivational interviewing focussing on drinking alcohol, and cigarette 
and cannabis smoking would successfully lead to reductions in use or problems.  Participants were 
daily cigarette smokers, weekly drinkers or weekly cannabis smokers.  The intervention group 
received one MI session, whilst the control group received no intervention.  At three month 
follow-up there were no differences between the two groups in terms of the number of cigarettes 
smoked in the previous week.  A greater proportion of the MI group than the control group 
reported trying to cut down or quit one or more times over the study period, however (73% vs 
45%). 
MI in adults 
In a randomised controlled trial, Chan 2011 ++, examined the effectiveness of motivational 
interviewing based smoking reduction counselling plus free nicotine replacement therapy for 
smokers not willing to quit. Two intervention groups received three 15 minute face-to-face 
smoking reduction counselling session based on MI techniques and the 5R approach, although the 
fidelity of the MI is unclear. The first group also received three minutes of information on 
adherence to NRT whilst the second group did not. Free NRT was provided in both groups, with a 
choice of patch or gum being available. A control group received simple cessation advice at 
baseline.  Results were presented for both intervention groups together. At six month follow-up 
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more participants in the intervention groups had achieved biochemically validated reductions of 
at least 50% than in the control group (OR 2.2, 95% CI 1.4,3.5; p=0.001). Differences between 
groups in self-reported quit rates were significant (p=0.01) but biochemically verified quit rates 
were not (OR 1.9, 95% CI 1.0, 3.7; p=0.07). The authors identified problems, however, in achieving 
biochemical verification among many of the participants. 
Carpenter 2004 + carried out a quasi-RCT comparing the effects of motivational treatment and 
behavioural reduction aided by NRT with no treatment control. Participants in the motivational 
treatment group received three motivational and advice giving telephone calls over six weeks, 
with advice to quit being given in the final call. The fidelity of this MI intervention is unclear. 
Those in the reduction aided by NRT group also received three telephone calls with the focus 
being on behavioural reduction strategies and problem solving advice being given where 
necessary. Participants in this group could also choose to receive nicotine gum or patches, and 
again advice was given to quit at week six. At follow-up, 24 weeks post-baseline, participants in 
both experimental groups who continued to smoke were smoking less than those in the no 
treatment condition (p<0.05), although there were no differences between the two experimental 
groups. Higher numbers of participants in the intervention groups than in the no treatment group 
had cut their smoking in half (circa 20% vs 11%), although significance values were not reported.  
Over the six month study period both intervention groups were more likely than the no treatment 
group to make a 24 hour quit attempt (reduction group OR 4.2 95% CI=2.6-6.7, motivational 
group OR 5.6 95% CI=3.5-9.1). The reduction group were less likely than the motivational group to 
make a quit attempt, although this difference was not significant (OR 0.7 95% CI=0.5-1.1). A 
greater number of participants in both intervention groups also achieved seven day point 
prevalence abstinence than in the no treatment group (p<0.01). 
In an RCT, Davis 2011 + compared the effectiveness of brief motivational interviewing versus 
prescriptive counselling among adult smokers who were not ready to quit. The intervention was a 
15 minute MI session delivered in a laboratory setting, designed to match the time available in 
the average professional-patient interaction. The control group received a 15 minute prescriptive 
interview, also delivered in a laboratory setting.  Outcomes were measured at one and six-months 
post-intervention and included intentions to quit or reduce smoking, verbal report of reducing 
cigarette consumption by 50% or quitting, and biologically verified quitting or reductions of 50%. 
At follow-up there were no differences between groups on any of the outcome measures.  
MI in military veterans 
Gulliver 2008 + carried out a quasi-randomised controlled trial in which they investigated the 
differential efficacy of three brief motivational interviewing interventions to yield changes in 
smoking behaviour among psychiatrically complex military veterans. No information is provided 
on whether the interventions were monitored for fidelity to MI practices. The three intervention 
groups were MI plus instruction in deep breathing (MI/BI), MI plus instruction in use of an 
incentive spirometer for practice in breathing/diaphragmatic control (MI/IS), and MI alone.  
Across all conditions the MI component consisted of one single session lasting 40 to 50 minutes.  
At six month follow-up there was no difference between treatment groups on either or cigarettes 
per day (p>0.65) or point prevalence abstinence (p>0.30). CO levels fell from baseline to 6-month 
follow-up in the MI/BI and MI/IS groups, but increased in the MI group. Those receiving MI/BI had 
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significantly lower CO levels during follow-ups than those receiving MI/IS (p=0.003; no useable 
data; graphical presentation only). Differences between MI/IS and MI were non-significant 
(p=0.12).  
Meta-analysis of motivational interviewing interventions 
The possibility of undertaking a meta-analysis to examine reduction-related outcomes for 
motivational interviewing interventions was explored. However, there was considerable clinical 
heterogeneity in reported outcomes for smoking reduction and no two studies used exactly the 
same measures.   
Only one outcome (abstinence) was sufficiently homogeneous in terms of measures to allow 
pooling of data. A pragmatic meta-analysis was conducted, including all studies that reported a 
cessation measure (Figure 4.1 Plot A).  
 
Figure 4.1 – Long term smoking cessation in motivational interviewing (MI) versus non-MI based 
interventions, split by composition of intervention 
Plot A – Analysis of all MI studies compared to control 
 
[Note: Brief = single session; Intensive = multiple sessions] 
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Plot B - Sensitivity analysis of MI (no NRT) compared to control 
 
 
 
Plot C – Sensitivity analysis of MI compared to non-intensive control 
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Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Chi² = 0.27, df = 1 (P = 0.60), I² = 0%
Events
1
7
7
15
1
1
16
Total
109
30
84
223
40
40
263
Events
0
4
3
7
1
1
8
Total
109
26
78
213
34
34
247
Weight
6.1%
50.1%
35.6%
91.7%
8.3%
8.3%
100.0%
M-H, Random, 95% CI
3.00 [0.12, 72.84]
1.52 [0.50, 4.60]
2.17 [0.58, 8.09]
1.82 [0.80, 4.14]
0.85 [0.06, 13.08]
0.85 [0.06, 13.08]
1.71 [0.78, 3.75]
MI Non-MI Risk Ratio Risk Ratio
M-H, Random, 95% CI
0.005 0.1 1 10 200
Favours other care Favours MI
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Seven studies, three RCTs and four quasi-RCTs (Chan 2011++, Horn 2007 +, McCambridge 2005 +, 
Audrain-McGovern 2011 +, Carpenter 2004 +, Davis 2011 +, Kelly 2006 +,)6 were pooled (Figure 
4.1 Plot A) with a risk ratio of 2.03 (95% CI 1.2, 3.6; p=0.01; I2=46%) and an NNT of 20 (95% CI 10, 
α7). The analysis indicated that MI interventions led to an increase in the number of abstinent 
participants. However, as identified in Question 1, NRT usage on its own increases the likelihood 
of smoking cessation even in study populations not looking to quit.  
Two sensitivity analyses were conducted. The first (Figure 4.1 Plot B) excluded Carpenter 2004 + 
and Chan 2011 ++. These studies combined a motivational component with NRT which may have 
biased the estimate treatment effect upward. Additionally, the fidelity of the motivational 
component is unclear in both studies. This analysis indicates that motivational interviewing is not 
effective for abstinence: RR 1.34 (95% CI 0.75, 2.39; p=0.32).  
The second sensitivity analysis (Figure 4.1 Plot C) also excluded Audrain-McGovern 2011 + which 
used an intensive control that could potentially cause a downward bias of the overall treatment 
effect. Excluding this study did not result in any significant difference: RR 1.71 (95% CI 0.8, 3.8; 
p=0.18). 
Overall the analyses indicate that MI interventions are not effective in increasing abstinence in 
study populations not looking to quit smoking. However, adding NRT to a motivational 
component may improve the likelihood of a positive outcome: RR 3.09 (95% CI 1.06, 9.01; p=0.04) 
Behavioural studies using other techniques 
Behavioural interventions for subjects with mental health problems 
One RCT Schleicher 2010 + and one small UBA (Roll 1998 −) looked at behavioural interventions 
for subjects with mental illness. 
Schleicher 2010 + carried out an RCT examining smoking reduction and cessation among college 
smokers with elevated depressive symptoms.  Participants took part in six group-based multi-
component cognitive behaviour therapy based intervention including mood management, 
behavioural counselling, and motivational enhancement.  Control group participants received six 
sessions designed to increase the consumption of fruit and vegetables.  The follow-up period was 
one month after the end of treatment.  No significant differences emerged between groups in 
terms of either the proportion who reduced their smoking levels by 50% or 30-day point 
prevalence abstinence.    
Roll 1998 – explored the effect of intensive contingent positive reinforcement with cash 
payments for adults with schizophrenia.  By the end of two weeks intensive therapy expired CO 
levels had dropped to an average of 15.9 ppm compared to the baseline measure of 37 ppm.  
However, by 8 weeks post participation the average level (36.8 ppm) had returned to baseline. 
  
                                                          
6
 Participant motivations were unclear for three studies (Horn 2007 +, Kelly 2006 +, McCambridge 2005 +). In the 
remaining studies participants did not have to be interested in quitting (Audrain-McGovern 2011 +) or they did not 
want to quit (Carpenter 2004 +, Chan 2011 ++, Davis 2011 +).   
7
 α symbol indicates infinity 
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Telephone counselling among adults 
In an individual randomised controlled trial, Glasgow 2009 ++ examined the effectiveness of a 
smoking reduction programme relative to enhanced usual care among adult patients scheduled 
for outpatient surgery or a diagnostic procedure.  Participants in the intervention group received 
a combination of telephone counselling sessions and tailored newsletters.  At the 12 month 
follow-up there were no significant differences between intervention and control groups in terms 
of numbers reducing their daily cigarette consumption by ≥50% or in carbon monoxide levels. 
Computer aided reduction versus reduction via manual instruction in adults 
Riley 2002 + tested the feasibility of two self-help behavioural treatments for smoking reduction 
via a randomised non-controlled trial.  The first approach was Computerised Scheduled Gradual 
Reduction (CSGR).  In this approach a computer programme was used to schedule a reduction to 
50% of baseline levels, prompting cigarettes at intervals to achieve this. After the two week 
reduction period, there was a two week maintenance period comprising a fixed schedule to 
maintain the 50% reduction. The second approach was Selective Elimination via manual 
instruction (SER). In this approach participants determined the daily reduction by using a table in 
the manual. Once the goal of 50% reduction was achieved, participants again completed a two 
week period at which this smoking level was maintained. Telephone follow-up interviews took 
place six and 12 months after the start of the study. The difference between groups in % 
reduction in smoking from baseline was not significant at 12 or six months.  The numbers of 
subjects achieving ≥50% reduction in CPD compared to baseline was 18.2% for CSGR versus 18.4% 
for SER.   More CSGR than SER participants were abstinent or had made a 24 hour quit attempts 
at 12 month follow-up, although the differences between groups were not statistically significant. 
Effectiveness of providing safer smoking tips to adult smokers 
Cunningham 2006 + carried out a quasi-randomised controlled trial testing the hypothesis that 
framing health information as safer smoking tips might motivate change in smoking behaviours. 
Adult smokers completed questionnaires. Those in the intervention condition were asked if they 
knew about a range of harm reduction techniques whilst those in the control group were simply 
asked to report their current harm reduction activities, with no information on harm reduction 
techniques being provided. At the three month follow-up point those who received safer smoking 
tips reported a small reduction in the number of cigarettes smoked compared to those in the 
control condition (p=0.05). Overall levels of change in cigarettes per day were small, however, and 
the mean number of cigarettes per day remained high in both groups at follow-up (C=21.1 +/- 
12.2 CPD at baseline and 23.1 +/- 14.1 CPD at follow-up, I=23.2 +/- 8.1 CPD at baseline and 20.1 
+/- 8.4 CPD at follow-up).  
Workplace self-help programmes for adults 
Borland 1999 + developed programs to assist smokers in coping with workplace smoking bans 
and, in a cluster randomised controlled trial, compared outcomes associated with two types of 
reduced smoking interventions to those of a control condition. The first intervention was a group 
programme in which weekday smokers who responded to the workplace survey were given a self-
help manual and were offered four sessions in a facilitator led group programme. The second 
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intervention group received the manual only. There were no significant differences between 
groups on any outcomes at the six month follow-up. 
Genetic testing and counselling 
A secondary analysis of a UBA, Carpenter 2007 −, suggested that a smoker’s knowledge that they 
had alpha-1-antitrypsin (AAT) deficiency, having volunteered for testing, could influence quit 
attempts and CPD. Odds of quit attempt were 3.3 x higher (95% CI 1.1, 10.0) among AAT deficient 
versus non deficient individuals. There were no group differences in abstinence at 3 months. 59% 
of severely AAT deficient smokers reduced their CPD by ≥50% compared with less than 20% in 
carriers and non-carriers. 
Use of a personal CO monitor 
Beard 2012, an uncontrolled before and after study in 10 participants, looked at whether use of a 
personal CO monitor would be effective in reducing CPD and in abstinence. Results at six weeks 
were not statistically significant for CPD reduction: baseline 14.1 CPD (SD 6.03); 6-week follow-up 
9.5 (SD 5.50); (p=0.127). 
Behavioural techniques in combination with nicotine replacement therapy (NRT) 
Cognitive behavioural therapy (CBT) and NRT in adolescents 
Hanson 2008 + examined via an individual randomised open-label trial whether adolescents not 
interested in quitting could reduce cigarette consumption. Participants were allocated to receive 
nicotine patch, nicotine gum, or a folic acid pill control condition. Nicotine patch (up to 21 mg) 
and gum doses (one 2 mg piece for each cigarette) were recommended according to participants’ 
baseline smoking levels. Participants also met weekly for six weeks and received CBT designed to 
help reduce smoking. Participants were told to gradually reduce their smoking over the course of 
the weeks.  After the reduction period participants were asked if they wanted to set a quit date 
within one week. If they chose to do so they received four additional weeks of their choice of 
medication and CBT sessions designed to help them quit. Follow-up took place at three and six 
months, and outcomes were measured in relation to reduction in number of cigarettes per day, 
expired carbon monoxide levels, urinary cotinine levels, and smoking cessation. Across all groups 
participants reduced the mean number of cigarettes smoked per day both at the end of treatment 
and at the follow-up visits. There were no differences across groups at either of the follow-up 
time points for any of the smoking related variables (all p>0.05).  
Counselling combined with NRT among adults 
Joseph 2008 + carried out a smoking RCT comprising counselling and adjunctive nicotine 
replacement therapy among adult smokers. Different behavioural strategies for reducing cigarette 
consumption were described to participants, who then chose the strategy that was most 
appealing to them. In addition participants substituted 4mg nicotine gum for each cigarette, 
switching to a patch if using more than six pieces of gum a day or if not reducing with gum alone. 
Control group participants had an initial visit to a counsellor to encourage the participant to seek 
cessation assistance but received no other counselling or pharmacotherapy. There were no 
significant differences between groups for reduction or abstinence at any of the three follow-up 
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points (6, 12 and 18 months). There were also no significant differences between groups in terms 
of changes in cotinine and expired carbon monoxide levels.  
In a small subgroup of an RCT primarily aimed at smoking cessation (Pisinger 2005a −) the 
outcomes were explored for 39 adult smokers who did not wish to quit and who were provided 
with a lifestyle consultation, the opportunity to attend 6 smoking reduction group sessions and 
NRT of the participant’s choice (patch, gum, inhaler, tablet). At six months, mean CO reduction 
was 10% for 39 eligible participants (no raw data presented). Authors state that data were too 
limited for further analyses.  
Finally, a weak UBA (Hurt 2000 −) looked at the effect of 6-16 nicotine inhaler cartridges per day 
(ca 5 mg NRT per cartridge) and 12 weekly behavioural counselling sessions with a smoking 
reduction schedule for heavy smokers (≥ 40 CPD at baseline). Inhaler use was inversely associated 
with smoking rate but across the study population, CO levels (ppm) were not significantly reduced 
from baseline at any measured time point. Baseline: 30.4 ± 9.0, 12 weeks: 24.1 ± 8.3, 24 weeks: 
26.0 ± 8.0.  
Behavioural support combined with NRT among adults with mental illness 
A small UBA, Griffiths 2010 –, concluded that 12 weekly counselling sessions using the Tobacco 
Addiction Recovery Programme (TARP) with free NRT (no details) could help adults with severe 
and persistent mental illness reduce their smoking.  From an analysis of the 38 completers only 
(61% of the original population) immediately following the intervention, 44% reported that they 
had quit smoking. Among the reducers, 78% reported that they had reduced smoking by ≥ 50%.   
There was no biochemical validation of these results.  
A very small study examined sequential 5-day interventions in regular smokers with schizophrenia 
or schizoaffective disorder.  Tidey 2002 –, explored contingency management (CM; payments for 
reduction) plus 21 mg nicotine patch (C+NIC), CM plus placebo patch (C+P) and non contingent 
monetary reinforcement plus placebo patch (NC).  Average CO levels during NC condition were 
significantly higher than during C+P and C+NIC conditions;  respectively 28.0 (SEM = 2.9), 20.5 
(SEM = 3.7) and 19.4 (SEM = 2.9) ppm (p<0.05). 
NRT + hierarchical reduction versus NRT + increased inter-cigarette interval  
A very small crossover quasi RCT (Riggs 2001 –) compared hierarchical reduction (HR; eliminating 
easiest to give up cigarettes first) to increased inter-cigarette interval (ICI) with, in both groups, ad 
libitum access to nicotine gum at 2mg or 4mg doses based on baseline CPD for the reduction in 
smoking. Each treatment lasted two weeks before cross over to the alternate treatment. There 
was a significant reduction in CO at the end of each treatment period (19% reduction HR vs 20% 
ICI (p<0.0001 in each case) with no difference between treatments. 
Pre-operative interventions, for abstinence on day of surgery 
A systematic review (Thomsen 2010 +), reviewed eight trials; of which two initiated multi-session 
face to face counselling at least six weeks before surgery, and six used a brief intervention. NRT 
was offered or recommended to some or all participants in seven trials. Five trials detected 
significantly increased smoking cessation at the time of surgery, and one approached significance; 
although the trials were not consistent in the definition of “at the time of surgery” and there were 
variations in the intensity of the support provided. Subgroup analyses showed that both intensive 
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and brief intervention significantly increased smoking cessation at the time of surgery; pooled RR 
10.76 (95% CI 4.55, 25.46) for two trials and RR 1.41 (95% CI 1.22, 1.63) for five trials respectively.  
Four trials evaluating the effect on long-term smoking cessation found a significant effect; pooled 
RR 1.61 (95% CI 1.12, 2.33). However, when pooling intensive and brief interventions separately, 
only intensive intervention retained a significant effect on long-term smoking cessation; RR 2.96 
(95% CI 1.57, 5.55) for two trials. 
Munday 1993 −, a controlled clinical trial, evaluated the effectiveness of a leaflet outlining 
reasons for stopping smoking prior to elective surgery with the recommendation to stop smoking 
at least 6 weeks before their operation. The intervention group was compared with a control 
group who had not been given any specific advice. There was no significant difference between 
groups for reported abstinence of more than 3 days, intervention=7.4% (95% CI: 5.1, 9.6) and 
control=9.3% (95% CI 6.4, 12.2), p>0.5. There was a trend for the participants in the intervention 
group to decrease cigarette consumption but this did not reach statistical significance, 
intervention= 40/136 and control =20/97 (p>0.1). 
A UBA (Walker 2009 −) evaluated the effectiveness of advice outlining the risks of smoking 
associated with forefoot surgery and advice to stop smoking prior to surgery. Advice was given to 
patients approximately 6 months before elective forefoot osteomy or arthrodesis and reiterated 
at pre-operative clinic. Based on self-reported outcomes sixteen (64%) of the smokers stopped 
smoking prior to surgery, four (16%) reduced smoking and 2 (8%) were not influenced. 
Interventions to reduce children’s exposure to environmental tobacco smoke  
Four studies (1 RCT, 1 quasi-RCT, one non-RCT and a CBA) reported parental smoking reduction 
outcomes. Interventions ranged from brief information and advice to a series of individualised 
counselling sessions over several months. Two studies targeted parents of asthmatic children. 
Outcomes of interest (reduction or abstinence in parents) were generally secondary outcomes 
and only limited data were available. 
An RCT (Hovell 2000 ++) evaluated the effectiveness of seven individualised counselling sessions 
over three months (three face to face and four by telephone) in low-income Californian mothers. 
The control group received one session of brief advice about smoking and child ETS exposure. At 
twelve months from start of treatment, there was a non-significant decrease (p=0.06) in 
counselled mothers’ cotinine concentrations (80.6ng/ml) compared with the control group 
(112.9ng/ml). There was also no significant difference in the number of mothers who had ceased 
smoking (counselling = 6/53; brief advice = 4/55). 
A quasi-RCT (Irvine 1999 +) investigated the effectiveness of advice and information to parents of 
asthmatic children. Parents in the intervention group were visited and  given information on the 
impact of passive smoking on asthma, followed by a discussion and advice to quit smoking or, if 
this was not possible to reduce child’s exposure. They were also provided with a general leaflet 
and another specifically designed to reinforce information. Specifically designed follow-up leaflets 
and letters were sent by post four and eight months after the initial meeting. A control group was 
provided with the general leaflet only. One year post-visit, based on self-reported CPD, 59 (28%) 
of the intervention group and 55 (25%) of the control group smoked less; 59 (28%) and 55 (25%) 
respectively smoked same amount; 58 (27%) and 47 (21%) respectively smoked more (p=65). 
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Twelve parents reported they had ceased smoking: seven in the intervention group and five in the 
control group. None of these differences was significant. 
A non-randomised controlled trial (Wakefield 2002 +) also included parents of asthmatic children. 
The study compared written and verbal feedback on child urinary cotinine levels supplemented by 
information booklets and two telephone calls, to usual care for parents visiting an Australian 
hospital paediatric asthma outpatient clinic. The study population comprised 58% low-income 
families with a household income of less than Aus$20,000 per annum and the employment rate of 
fathers was 80% compared to an average of 90-95% in the general population. At six months, 
mean change reduction in cigarettes per day from baseline was not significant for mothers 
[intervention group -0.17 (95%CI: -1.62, 1.27), control group -0.94 (95%CI: -1.90, 0.02) p= .40] or 
fathers [Intervention group -1.51 (95%CI: -3.61, 0.59); control group -1.20 (95%CI: -3.28, 0.88) p= 
.80]. There was no significant impact on cessation with no parents in the intervention group and 
three parents in the control group biochemically verified as abstinent.  
A  CBA (Fossum 2004 −) evaluated the impact of training Swedish community health nurses 
(CHNs) working with post-partum mothers in a counselling method “Smoke-free children”. 
Mothers’ self-reported CPD consumption was cotinine-verified for 22 of 26 mothers receiving care 
from CHNs trained in the counselling method and 8 of 14 mothers receiving care from CHNs not 
trained in the method. There were no statistically significant differences between groups for 
measures from baseline (B) at one month before birth and follow-up (FU) three months after 
birth. Mean CPD (SD) for intervention:  B = 12.7 (6.6); FU = 12.9 (6.2) and control: B = 8.4 (3.9); FU 
= 7.1 (2.8). 
Evidence Statements:  
4.1 there is consistent evidence from seven studies (2 RCTs, 4 quasi-RCTs and 1 CBA) (Horn 
2007 +, McCambridge 2005 +, Kelly 2006 +, Audrain-McGovern 2011 +, Davis 2011 +, 
Gulliver 2008 +, Gray 2005 −) that motivational interviewing compared with other 
behavioural methods or with no support and whether provided in single or multiple 
sessions, is not effective in helping people to reduce smoking levels. This evidence 
applies to healthy adolescents and adults, with no statistically significant between group 
differences reported across any of the studies reviewed. Weak evidence also exists for 
the lack of effectiveness of motivational interviewing for adolescent drug users 
(McCambridge 2005 +, Gray 2005 −) and military veterans with psychiatric problems 
(Gulliver 2008 +), with these studies again finding no significant between group 
differences for the outcomes reported.   
4.2 There is strong evidence from a meta-analysis of two RCTs and three quasi-RCTs (Horn 
2007 +, McCambridge 2005 +, Audrain McGovern 2011 +, Davis 2011 +, Kelly 2006 +) 
that motivational interviewing, compared with other behavioural methods or with no 
support and provided in single or multiple sessions, is not effective for smoking cessation 
in populations unable or unwilling to stop smoking: RR 1.34 (95% CI 0.75, 2.39; p=0.32). 
This is at variance with findings of a Cochrane systematic review of MI for smoking 
cessation (Lai 2010). The addition of NRT to a motivational component (Chan 2011 ++, 
Carpenter 2004 +) may improve the likelihood of abstinence: RR 3.09 (95% CI 1.06, 9.01; 
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p=0.04).  
4.3 There is moderate evidence from a large well-conducted RCT (Chan 2011++) that NRT 
combined with a motivational component is effective, with a significant CO-validated 
≥50% 7-day point prevalence reduction rate. 
4.4 There is strong to moderate evidence from four studies (1 RCT, 1 quasi-RCT, one non-
RCT and a CBA) designed to reduce the impact of environmental tobacco smoke on 
children (Hovell 2000 ++, Irvine 1999 +, Wakefield 2002 +, Fossum 2004 −) of no effect 
for a variety of behavioural methods versus standard care in reducing parental smoking. 
This evidence applies to parents of children with asthma (Irvine 1999 +, Wakefield 2002 
+) as well as to parents of healthy children (Hovell 2000 ++, Fossum 2004 −). 
4.5 There is moderate evidence from two RCTs (Hanson 2008 +, Joseph 2008 +) and one 
UBA (Hurt 2000 −) that counselling combined with nicotine replacement therapy is not 
effective in helping adolescents (Hanson 2008 +) or adults (Hurt 2000 −, Joseph 2008 +) 
to reduce their cigarette consumption or to ultimately quit.  There were no differences 
at follow-up between intervention and control groups for any smoking related oumes. 
4.6 There is moderate evidence from one RCT (Glasgow 2009 ++) that telephone counselling 
is an ineffective approach to reducing cigarette consumption.  At the 12 month follow-
up there were no significant differences between intervention and control groups in 
terms of numbers reducing their daily cigarette consumption by ≥50% or in carbon 
monoxide levels. 
4.7 There is moderate evidence from one quasi-RCT (Riley 2002 +) that computer-aided and 
manual-aided approaches to assist with reduction had similar effect sizes. Twelve 
months after the start of the study there were no differences between groups in 
smoking reduction, and although more participants in the computer-aided group had 
made a quit attempt than in the manual-aided group, this difference was not statistically 
significant. 
4.8 There is moderate evidence from one systematic review of pre-operative smoking 
interventions (Thomsen 2010 +) that counselling combined with NRT increases smoking 
cessation at the time of surgery for both brief and intensive interventions. However only 
intensive interventions were effective at 12 month follow-up. RR 2.96 (95% CI 1.57, 
5.55) for two trials.  
 4.9 There is weak evidence from one quasi-RCT (Carpenter 2004 +) that both NRT aided 
reduction and motivational treatment are more effective than no treatment both in 
terms of reducing smoking and ultimately quitting. There were no significant differences 
between the two intervention groups on any outcomes (all self-reported).  This finding is 
at odds with those reported in the other behavioural studies. 
4.10 There is weak evidence from one RCT (Schleicher 2010 +) and one small UBA (Roll 1998 
−) that cognitive behavioural therapy is not effective in helping smokers to reduce their 
cigarette consumption or to reduce and ultimately quit.  
4.11 There is weak evidence from one quasi-RCT (Cunningham 2006 +) that providing safer 
smoking tips can have a marginal effect on reduction.  At three months follow-up those 
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who received safer smoking tips self-reported a small reduction in the number of 
cigarettes smoked compared to those in the control condition (p=0.05). Overall levels of 
change in cigarettes per day were small, however, and the mean number of cigarettes 
per day remained high in both groups at follow-up. 
4.12 There is weak evidence from one quasi-RCT (Borland 1999 +) that a self-help programme 
to assist smokers in coping with workplace smoking bans may not be effective.  At the six 
month follow-up there were no differences between groups on any of the outcomes 
assessed. 
4.13 There is weak evidence from one non randomised study and one UBA (Munday 1993 –, 
Walker 2009 –) that brief advice alone for pre-operative smoking cessation is not 
effective in achieving pre-operative abstinence. 
4.14 There is very weak evidence from a UBA (Carpenter 2007–) that knowledge of alpha-1-
antitrypsin (AAT) deficiency is effective in influencing quit attempts and cigarette 
consumption. 
4.15 There is very weak evidence from two UBAs (Griffiths 2010 –, Tidey 2002 –) that 
behavioural support combined with NRT is effective in reducing smoking among adults 
with mental illness. 
4.16 There is very weak evidence from one quasi-RCT (Riggs 2001 –) of no difference between 
NRT and hierarchical reduction versus NRT and increased inter-cigarette interval in 
reducing smoking. 
4.17 There is very weak evidence from one small UBA (Beard 2012) that a personal CO 
monitor is not effective in reducing CPD and encouraging abstinence. 
The majority of evidence is applicable to the UK as the studies are feasible in UK settings. 
However Carpenter 2007 –, Griffiths 2010 –, Hanson 2008 +, Tidey 2002 – are noted to have 
issues regarding applicability. Studies of specific populations included Kelly 2006 +, Audrain-
McGovern 2011 +, Hanson 2008 +, Horn 2007 + (adolescents); Gray 2005 –, McCambridge 2005 
+ (adolescent drug users); Gulliver 2008 + (military veterans); Griffiths 2010 –,Schleicher 2010 
and Tidey 2002 – (mental health); Munday 1993 –, Thomsen 2010 +, Walker 2009 – (patients 
undergoing elective surgery); Hovell 2000 ++, Fossum 2004 –, Irvine 1999 +, Wakefield 2002 + 
(parents).   
 
Q5. Is there an optimal period for helping people cut down or abstain from smoking, temporarily or 
indefinitely without the aim of quitting? 
 None of the studies looked specifically at this issue. The supported reduction periods in the 
included studies varied greatly from a single behavioural session at baseline to 18 months support 
and designs were heterogeneous so it is not possible to draw conclusions based on the evidence 
available. 
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Evidence Statement:  
5.1 No studies were found that looked at the effect of different reduction periods in helping 
people to cut down or abstain from smoking. 
 
Q6. Is it more or less effective to draw up a schedule to help people cut down or abstain from 
smoking, temporarily or indefinitely without the aim of quitting?  
Four studies of moderate to poor quality included some form of scheduled reduction; two quasi-
RCTs (Riggs 2001 −, Riley 2002 +) and two UBAs (Hatsukami 2005 −, Hurt 2000 −). None of these 
studies compared scheduled with non-scheduled reduction.  All four studies were conducted in 
the USA. 
Riggs 2001 −, a quasi-randomised study of 20 participants used a within-subject crossover design. 
A baseline week of smoking as normal was followed by one of two scheduled reduction methods 
over the next two weeks. Either participants increased their inter-cigarette intervals (ICI), or they 
eliminated cigarettes by hierarchical reduction (HR). For ICI, the mean baseline inter-cigarette 
interval was calculated and participants increased intervals between cigarettes by 25% in the first 
week and doubled these in the second week; resulting in a 50% decrease in CPD. HR required 
eliminating the 25% of cigarettes rated easiest to give up during first week and the easiest 
remaining 50% during the second week. In weeks 4-5 a baseline of normal smoking was re-
established with participants using the second reduction schedule.  All participants given nicotine 
gum to be used ad libidum, and encouraged to chew one piece of gum for each cigarette 
eliminated. Self-reported CPD reductions were significant:  10/20 (50%) of participants reduced 
their smoking by at least 50% by the end of ICI treatment and 6/20 (30%) by the end of HR 
treatment (p<0.0001). There was also a significant reduction in CO for both treatments: 20% for 
ICI and 19% for HR (p<0.0001) with no difference between treatments. There was no significant 
difference in self-reported ease of reduction:  ICI: 5.8 (±2.7); HR: 5.0 (±2.4). 
Riley 2002 +, a quasi-RCT, compared Computerized Schedule Gradual Reduction (CSGR) with 
Selective Elimination Reduction via manual instruction (SER). Both conditions received a manual 
providing equivalent information - advice on relapse prevention techniques and condition-specific 
information. In week one, The CGSR group established baseline smoking by pressing a ‘smoke’ 
button when they smoked whilst the SER group recorded CPD manually in a smoking diary. 
Subsequently during the two-week reduction phase CGSR participants were given a computer 
program which scheduled a reduction to 50% of baseline; prompting cigarettes at intervals to 
achieve this. The program could be adjusted (and lengthened) if subjects were having difficulties. 
Once 50% reduction had been achieved, a two-week fixed schedule was provided to maintain 50% 
reduction. The SER group used a table in the manual to determine daily reduction during the two-
week reduction phase. Once the goal of 50% reduction was obtained, subjects completed a 2 
week period during which this smoking level was maintained. In those who completed all time 
points (45/93) there was no significant difference between groups on any measure: reduction in 
CPD by at least 50% at either 12 months (CSGR = 18.2%, SER = 18.4%) or six months (CSGR = 
18.2%; SER = 12.2%); 11.4% of CSGR vs 6.1% of SER particpants were abstinent at 12 months. A 
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mean reduction of approximately 10 CPD from pre-treatment to post treatment occurred in both 
groups and was maintained over one year. 
In what was reported essentially as an uncontrolled study (Hatsukami 2005 −) participants were 
given 4 mg gum and instructed to reduce CPD from baseline levels to 75% in first 2 weeks, 50% in 
weeks 3-4 and 25% in weeks 5-6 (the control group received treatment after a six week delay). 
Those who found it difficult to achieve 50% or 75% goals offered 14mg nicotine patch to be used 
with gum. Participants were instructed on various methods to achieve reduction (substitution, 
timed interval use and situational use). At 26 weeks from baseline 41 of the 151 participants 
(27%) had achieved a reduction in CPD of at least 40% and 11 (7%) had achieved biochemically 
verified 30 day abstinence.  
A pilot study in 23 heavy smokers (Hurt 2000 –), provided short weekly counselling sessions (10-
15 minutes) plus a nicotine inhaler for twelve weeks and instructed participants to reduce from 40 
or more to 10 CPD using a schedule:  weeks 1-4 to 30 CPD; weeks 5- 8 to 20 CPD; weeks 9-24 to 10 
CPD.  Subjects asked to use ≥6 but no more than 16 5 mg nicotine inhaler cartridges per day.  For 
the sixteen who completed the study CPD fell from 41.9 ± 3.2 at baseline to 26.7 ± 10.8 at 24 
weeks.  CO levels were not significantly reduced from baseline at any measured time point 
(baseline: 30.4 ± 9.0; 24 weeks: 26.0 ± 8.0). 
Evidence Statements:  
6.1 Weak evidence from 2 quasi-RCTs and 2 UBAs (Riggs 2001 −, Riley 2002 +, 
Hatsukami 2005 −, Hurt 2000 −) suggests the use of a schedule may assist in 
reducing smoking. Schedules included week on week reduction (Hatsukami 2005 −, 
Hurt 2000 −), increased inter-cigarette interval or selective elimination (Riggs 2001 
−, Riley 2002 +). 
6.2 There is limited evidence from 2 quasi-RCTs (Riggs 2001 −, Riley 2002 +) of no 
difference in effect between different types of schedule (increasing inter-cigarette 
intervals or selective elimination). 
The evidence is partially applicable to people in the UK since all four studies were 
community based (in the USA) and are feasible in UK settings.  
 
Q7. Do some tobacco harm-reduction approaches have a differential impact on different groups (for 
example, people of different ages, gender, socio-economic status or ethnicity)? 
Included studies looked at several relevant populations: adolescents, ethnic groups, low income 
families and those with mental health problems,. 
Adolescents 
Five moderate and one poor quality study had adolescent populations; four looking at healthy 
populations (Audrain McGovern 2011 +, Hanson 2008 +, Horn 2007 +, Kelly 2006 +) and two at 
drug/alcohol users (Gray 2005 −, McCambridge 2005 +). One of these studies (Hanson 2008 +) 
THR 3.3 Review 3 - Effectiveness of tobacco harm reduction approaches without the prior intention of quitting with and without 
assistance 
 
 
 
65  
 
used a combination of behavioural therapy and NRT; the other five used motivational 
interviewing techniques.  
As noted in Question 4 above, no statistically significant between group differences were 
reported in any of the studies reviewed. 
Two studies were carried out in the UK (Gray 2005 −, McCambridge 2005 +) and one in Australia 
(Kelly 2006 +). These studies are all applicable to a UK setting, although the UK studies are in a 
specific population of drug and alcohol users. The remaining three studies (Audrain McGovern 
2011 +, Hanson 2008 +, Horn 2007 +) were conducted in the USA and their applicability is less 
certain.  
Ethnicity 
Two papers looked at ethnic populations. Audrain McGovern 2011 + was set in the USA and Chan 
2011 ++ in China. In a mixed race population of American adolescents (40% white, 45% black, 15% 
other/mixed race), a quasi RCT (Audrain McGovern 2011 +) found that regardless of allocated 
group, white adolescents were approximately 80% less likely to attempt to cut back (OR= 0.21, 
95% CI 0.08, 0.53) and more than 80% less likely to attempt to quit than black adolescents 
(OR=0.17 95% CI 0.06, 0.46). 
Chan 2011 ++, an RCT, examined the effectiveness of motivational interviewing based smoking 
reduction counselling plus free nicotine replacement therapy for smokers in Hong Kong who had 
previously failed to quit. At six months, more participants in the intervention groups had achieved 
biochemically validated reductions of at least 50% than in the control group (p=0.001). 
Differences between groups in self-reported quit rates were significant (p=0.01) but biochemically 
verified quit rates were not (p=0.07).  
The applicability of the two studies to a UK population is unclear. 
Low income families 
A quasi-RCT of motivational interviewing in Australian adolescents (Kelly 2006 +) noted that study 
participants were from lower SES families (skilled workers). There were no significant between 
group differences in any measures at six months. 
Two studies in low-income families aimed to reduce the impact of environmental tobacco smoke 
on children. An RCT conducted in the USA (Hovell 2000 ++), and a non-randomised clinical trial 
conducted in Australia (Wakefield 2002 +) both found no evidence that behavioural interventions 
were effective in reducing parental smoking. 
Mental health 
Five small scale studies investigated interventions for mental health populations, one RCT 
(Schleicher 2010 +) in depressed college students, one quasi-RCT in “psychiatrically complex” 
military veterans (Gulliver 2008 +) and three uncontrolled studies in populations with severe 
mental illness (Griffiths 2010 −) or schizophrenia or schizoaffective disorder (Roll 1998 −, Tidey 
2002 −). One further study (Joseph 2008 +) noted that a high prevalence of mental health 
disorders among participants  (greater than 50% in both arms) limited study generalisability, but 
did not provide any data on this population.   
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Overall study quality in this population was limited with small populations and limited follow-up. 
With the exception of Gulliver 2008 +, study populations were between 11 and 58 participants 
and follow-up period varied between end of treatment and eight weeks post-intervention.  
An RCT (Schleicher 2010 +) found no significant difference between groups in a small CBT study in 
a population of depressed college students.  
In a quasi-RCT of a brief motivational interview for 208 “psychiatrically complex” military veterans 
(Gulliver 2008 +), no difference was found at six months post-treatment between groups on 
either point prevalence abstinence (p>0.30) or cigarettes per day (p>0.65).   
Griffiths 2010 –, concluded that 12 weekly counselling sessions using the Tobacco Addiction 
Recovery Programme (TARP) with free NRT (no details on type or dosage) could help adults with 
severe and persistent mental illness reduce their smoking.  From an analysis of 34 completers 
immediately following the intervention, 44% reported that they had quit smoking.  Among the 
reducers, 78% reported that they had reduced smoking by ≥ 50%.    
Two very small studies (Tidey 2002 –, Roll 1998 –) investigated the effect of contingent payment 
with and without NRT patches in schizophrenic or schizoaffective disordered participants. Both 
found a statistically significant difference during treatment but the effect declined rapidly post-
treatment.  
All five studies were conducted in the USA but there is no reason to assume that they are not 
applicable to a UK mental health population. 
Evidence Statements:  
7.1 There is moderate evidence from five studies (2 RCTs, 2 quasi-RCTs, 1 CBA) (Horn 2007 +, 
McCambridge 2005 +, Audrain McGovern 2011 +, Kelly 2006 +, Gray 2005 −) of no effect 
for motivational interviewing interventions in reducing smoking in adolescents. 
7.2 There is weak evidence from one quasi-RCT (Hanson 2008 +) that cognitive behavioural 
therapy (CBT) plus NRT is not effective in reducing smoking among adolescents. 
7.3 Weak evidence from one quasi-RCT in the USA (Audrain McGovern 2011 +) comparing a 
multi-session intensive MI intervention to multiple sessions of brief structured advice,  
suggests that white adolescents are significantly less likely than black adolescents to 
attempt to reduce or quit smoking. 
7.4 Moderate evidence from one high quality RCT (Chan 2011 ++) indicates that MI plus NRT 
was effective in reducing smoking in adult Chinese smokers who had previously failed to 
quit.  
7.5  There is weak evidence from one quasi-RCT (Kelly 2006 +) of no effect of MI on Australian 
adolescents from lower SES families. 
7.6 Moderate evidence from 1 RCT and 1 non-randomised study (Hovell 2000 ++, Wakefield 
2002 +) found no evidence of effect for behavioural interventions in reducing parental 
smoking in low income families.  
7.7 There no evidence of sustained effect of behavioural interventions from 4 studies (1 RCT 
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and 3 UBAs) (Schleicher 2010 +, Tidey 2002 –, Roll 1998 –, Griffiths 2010 –) in mental 
health populations.  
7.8 There is very weak evidence from two small UBAs (Tidey 2002 –, Roll 1998 –) of a ‘during 
treatment effect’ on carbon monoxide-verified reduction in mental health populations for 
contingency management with or without NRT. 
The evidence is partially applicable to people in the UK.  McCambridge 2005 + and Gray 2005 –
were both based in the UK, and Kelly 2006 + and Wakefield 2002 + were based in Australia 
where there is a similar smoking treatment service to the UK.  Of the remaining studies, Chan 
2011 ++, Griffiths 2010 – and Hovell 2000 ++ were based in the community and interventions 
may be feasible for the UK.    
 
Q8. Are there any unintended consequences from adopting a tobacco harm-reduction approach; for 
example, does it deter people from trying to cut down or abstain from smoking, temporarily or 
indefinitely? 
Motivation/readiness to quit 
Two studies (Carpenter 2004 +, Wennike 2003 +) suggest that NRT does not reduce subjects’ 
motivations to quit smoking. In a quasi-RCT looking at NRT aided reduction (R-NRT) versus 
motivational treatment (MI) or no treatment (NT). Carpenter 2004 + found that readiness to quit 
increased across all groups. By week 24, R-NRT and MI subjects had similar intentions to quit and 
these were significantly greater than NT participants (p<0.05; data in graph form only). In another 
quasi-RCT comparing nicotine gum (2 or 4 mg) to placebo gum, Wennike 2003 + found similar 
motivations to quit in both groups at 24 months: intervention: 4.7 (SD 2.8); placebo: 5.2 (3.2). 
It is likely that further evidence regarding smokers’ motivations in relation to smoking reduction 
will be provided within the barriers and facilitators review (Review 4). 
Differences in psychological characteristics 
Etter 2002 (linked to Etter 2007 +) found no difference in psychological characteristics between 
nicotine and placebo groups. Following the intervention, at 5 years (Etter 2007 +) the same 
proportion of participants was using NRT in all groups (nicotine = 12%, placebo = 9%; no 
treatment – 11%).   
Adverse events from long term NRT use 
Evidence from nine studies looking at NRT use for periods between 6 months and five years 
suggests that NRT is generally well tolerated with few serious adverse events. These findings are 
in keeping with those from Review 1 which concluded that “evidence from nine randomised 
controlled trials strongly suggests that adverse events are common when NRT is used for smoking 
harm reduction, but these tend to be mild or moderate and are rarely severe.” 
Over a 13 month study period Batra 2005 + found no serious adverse effects related to NRT (4mg 
gum) and no discontinuations reportedly resulting from side effects. During 24 months therapy 
with a 10mg nicotine/1mg menthol inhaler Bollinger 2000 ++ found throat irritation (14 vs 4; 95% 
THR 3.3 Review 3 - Effectiveness of tobacco harm reduction approaches without the prior intention of quitting with and without 
assistance 
 
 
 
68  
 
CI 1.13, 15.6) and coughing (13 vs 4; 95% CI 1.1, 10.6) were significantly more frequently reported 
in the active vs placebo groups. Carpenter 2004 + found that 21% of participants who used NRT (4 
mg gum or 7, 14, 21 mg patch) for reduction up to 24 weeks reported an adverse event compared 
to 9% of those who used NRT only for a quit attempt (week 6-24) (p<0.01). In an RCT of NRT aided 
reduction (15 mg patch, 4 mg gum, 10 mg inhaler or combination). 
Etter 2007 + followed up a population using NRT for smoking reduction at six months, two years 
and five years. Data on adverse events associated with NRT use were only reported at six months.  
Two deaths were reported in the NRT group which the authors state the deaths were unlikely to 
be due to treatment. No significant difference was identified between groups (p=0.25). 
Jiménez-Ruiz 2002 – noted that 5 patients (29%) continued to use 10-12 pieces of 4 mg nicotine 
gum per day up to 18 months though no adverse event data are reported. Joseph 2008 + in a 
study of patients with heart disease noted that serious events were approximately equally 
distributed in smoking reduction (4mg NRT gum) other than need for urgent cardiac care at 6 
months which was higher in the usual care group (n=0 SR vs n=5 UC, p=0.02). Over a 12 month 
period Kralikova 2009 + reported no unexpected events over 12 months use of nicotine gum (4 
mg) or inhaler (10 mg). Rennard 2006 + reported similar rates of adverse events and serious 
adverse events in both nicotine inhaler (10 mg) and placebo inhaler groups within a 12 month 
intervention. Adverse events reported by 159 subjects (I) and 147 subjects (C). Serious adverse 
events: 15 events reported by 9 subjects (I) and 13 events reported by 11 subjects (C). Wennike 
2003 + found similar adverse events over a 12 month intervention in both nicotine gum (2 or 4 
mg) and placebo gum groups (166 versus 147). 
Adverse events from e-cigarette use 
From a single UBA study of e-cigarette use over a 24 week period (Polosa 2011 –) the most 
frequent adverse events reported were mouth irritation (20.6%), throat irritation (32.4%) and dry 
cough (32.4%).  67.5% of participants completed the study. Findings from review 1 suggested that 
“there is no evidence on the long term safety of e-cigarettes, whether used alone or with 
concurrent cigarette smoking. There isn’t a large volume of reliable evidence on the short term 
safety of e-cigarettes.” 
Evidence Statements:  
8.1 There is strong evidence from eight studies reporting usage of NRT for periods between 
six months and five years (Batra 2005 +, Bollinger 2000 ++,   Etter 2007 +, Jiménez-Ruiz 
2002 –, Joseph 2008 +, Kralikova 2009 +, Rennard 2006 +, Wennike 2003 +) to suggest 
that NRT is generally well tolerated long term with severe side effects being relatively rare. 
8.2 There is moderate evidence from two quasi-RCTS (Carpenter 2004 +, Wennike 2003 +) 
that harm reduction interventions do not deter smokers from wishing to quit. 
8.3 There is weak evidence from a single UBA (Polosa 2011 –) that frequent adverse events 
are reported by e-cigarette users.  This finding supports the conclusions from Review One 
(Toxicity) that more evidence is required concerning the safety of e-cigarettes. 
Adverse event studies are likely to be applicable to the UK. 
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Comparison with two previous systematic reviews  
A Cochrane systematic review found within the literature search looked specifically at interventions to 
reduce harm from continued tobacco use (Stead 2010). A Health Technology Assessment (Wang 2008 also 
published as Moore 2009) initially identified for Review 2 looked at long term smoking reduction and 
abstinence in populations not willing or able to quit. Both reviews were unpicked for relevant primary 
studies as well as being briefly summarised here.   
Stead 2010 conducted a systematic review to assess the effect of interventions intended to reduce the 
harm from smoking on: biomarkers of damage caused by tobacco, biomarkers of tobacco exposure, 
number of cigarettes smoked, quitting, and long-term health status. Several interventions that are outside 
the scope of this review (bupropion, and tobacco containing products) were included; however, types of 
intervention were reported separately throughout.  
The review included 12 studies with NRT interventions, ten of which had been identified for inclusion in this 
review (Batra 2005 +, Bolliger 2000 ++, Carpenter 2004 + [also including a pilot Carpenter 2003], Etter 2007 
+ [included as Etter 2004], Hanson 2008 +, Joseph 2008 +, Kralikova 2009 +, Rennard 2006 +, Wennike 
2003). The two remaining studies were unpublished data from the manufacturer (Australia NNCG-017) and 
Haustein 2003, a conference abstract. Three behavioural intervention studies all identified for inclusion in 
this review (Glasgow 2009 +, Pisinger 2005 −, Riley 2002 +) were also included. 
The authors found that in a pooled analysis of nine studies NRT significantly increased the odds of reducing 
CPD by 50% or more compared to placebo at end of follow-up, RR 1.72; (95% CI 1.41, 2.10). Also in a pooled 
analysis of nine studies, NRT was found to increase the odds of quitting, RR 1.73 (95% CIU 1.36, 2.19) at end 
of follow-up. However there was no clear evidence of effect from behavioural interventions. 
A second systematic review of seven studies (published both as Wang 2008 and Moore 2009) looked at the 
impact of NRT on abstinence in populations not looking to quit. As with Stead 2010, all studies other than 
the two which were unpublished data (Australia NNCG-017/Wood Baker and Haustein) were included.  
Pooling results using a random effects model the review found statistically significant results for NRT versus 
placebo in both reduction and abstinence measures: sustained reduction to end of follow up RR, 3.84 (95% 
CI 2.32 to 6.35); point prevalence reduction at end of follow up, RR 1.32 (95% CI 1.14 to 1.54); sustained 
abstinence of at least six months, RR 1.99, (95% CI 1.01, 3.91). Additionally, the 12-month sustained 
abstinence rate was found to be approximately 5.3% for NRT versus 2.6% for the placebo group. 
Moore 2009 makes the point that most of the effectiveness evidence came from studies with considerable 
participant-investigator contact and suggests that to obtain similar rates of abstinence would require an 
enhanced level of service delivery in a real-world setting.  
However, it should be noted that any behavioural support, advice or contact was the same in both NRT and 
placebo groups and evidence from this review suggests a lack of effect for behavioural interventions.  
Overall the results of this review concur with those of Stead 2010 and Wang 2008/Moore 2009 in 
suggesting that, in populations not able or willing to quit, NRT may be effective for long term smoking 
reduction and abstinence.  In contrast, there is little evidence to support the use of behavioural 
interventions alone. 
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5. DISCUSSION 
This review contains a large body of evidence of relevance to long term harm reduction without the 
prior aim of quitting.  
Five studies were conducted in the UK, and six in countries with similar smoking treatment 
programmes. In general, applicability to the UK was good with many other studies based in the 
community.   
The quality of the included studies was variable with a wide variation in time periods and outcomes. 
There was a good body of consistent evidence for some topics and outcomes for NRT studies 
(measures of CPD, ≥50% reduction and continuous or point-prevalent abstinence) were generally 
consistent. By contrast, reduction outcomes for behavioural studies varied considerably and it was not 
possible to conduct meta-analyses other than for abstinence. Reduction outcomes were generally self-
reported so there is little information on reduction in exposure. However, where studies identify 
abstinence at follow-up and report this outcome, it is generally biochemically verified.  
Participant motivations were difficult to ascertain in some studies. Thus, the scope of the review 
included studies that were designed as long term harm reduction studies, as well as those where the 
included participants did not wish to quit smoking. 
All six randomised/quasi-randomised studies investigating the use NRT in the general population were 
either industry sponsored (Bolliger 2000 ++, Batra 2005 +, Kralikova 2009 +, Rennard 2006 +, Wennike 
2003 +), or the authors had financial ties to industry (Etter 2007 +).  As noted in Review 2, authors 
declared sources of funding and any potential conflicts of interest. However, a 2003 meta-analysis of 
RCTs included in a Cochrane review of smoking cessation interventions concluded that “Compared 
with independent trials, industry-supported trials were more likely to produce statistically significant 
results and larger odds ratios. These differences persisted after adjustment for basic trial 
characteristics.” (Etter 2003) The authors suggested that this difference may be the result of 
publication bias.  
By contrast, potential conflicts of interest were only identified in one behavioural study (Riley 2002 +) 
in which the computerised scheduled reduction intervention had been developed and was being 
marketed by a company employing the authors. 
Nine of the behavioural studies (three RCTs, five quasi-RCTs and one CBA) included a ‘motivational 
interview’ component as part of the intervention (Chan 2011++, Horn 2007 +, McCambridge 2005 +, 
Audrain-McGovern 2011 +, Carpenter 2004 +, Davis 2011 +, Gulliver 2008 +, Kelly 2006 +,  
Gray 2005 −); two studies combining that component with NRT (Chan 2011 ++, Carpenter 2004 +). The 
component ranged from a single brief interview to multiple intensive sessions. There appeared to be 
little difference in outcome between brief and intensive interventions. Fidelity to the principles and 
practice of motivational interviewing (Miller 2002) was also considered. Six of the seven studies 
looking at motivational interviewing alone identified key elements of principles and practice. Fidelity 
was unclear in both studies combining a motivational component with NRT.  
Overall, the evidence within the review suggests that:  
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 Across all studies of NRT versus placebo where reduction is an intended outcome, meta-
analyses indicate significant benefits from NRT. 
 NRT may also be effective for abstinence in the longer term in populations not looking to quit. 
 NRT supplementation may help reduce ad libitum smoking (where there is no instruction to 
reduce) but the evidence base is weak.  
 No evidence comparing combinations of NRT was found but it appears that there are no clear 
differences in effectiveness between different types of medication and some modest evidence 
that offering smokers a choice of medication may enhance efficacy. 
 Nicotine patch is effective in reducing post-operative smoking consumption in the short term 
but this is not maintained long term. 
 Evidence for the value of e-cigarettes to date is available only from a single UBA study and, 
although suggestive of benefit, no conclusions can be drawn as yet. We note that the MHRA is 
currently considering whether to regulate e-cigarettes and other nicotine-containing products. 
 Two studies suggest NRT combined with a brief motivational component may be effective for 
abstinence in populations not looking to quit. However, the impact of the motivational 
component is unclear.    
 There is consistent evidence that motivational interviewing alone, either in single or multiple 
sessions, is not effective as a long-term harm reduction strategy.  
 MI does not appear to be effective for abstinence in populations unable or unwilling to quit. This 
is at variance with the evidence from a Cochrane systematic review looking at the effect on 
abrupt cessation (Lai 2010); which found some evidence that MI may assist abstinence. The 
reason for this variance is not clear, although it may reflect the impact of the two statistically 
significant studies - Hollis 2007 and Soria 2006. In the first, which contributed considerable 
weight to pooled analyses, study participants had to be motivated to quit. In the second study 
bupropion was provided to a small proportion of the MI group, which may have skewed the 
results.   
 The evidence available for other types of behavioural intervention is weaker but it is also 
suggestive of no benefit. 
 Both brief and intensive pre-operative smoking interventions, combining counselling with NRT, 
increase smoking cessation at the time of surgery. However only intensive interventions were 
effective long term. 
 There is no evidence of effect on parental smoking levels from interventions to reduce 
environmental tobacco smoke. Results do not appear to vary between parents of asthmatics 
and those with generally healthy children. 
 No evidence was found to suggest an optimal reduction period. 
 Limited weak evidence suggests that scheduled smoking reduction may be more effective than 
non-scheduled smoking reduction; although there do not appear to be differences in effect 
between types of scheduled reduction.  
 There is very little evidence to distinguish the effectiveness of interventions across socio-
economic groups.  
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 The small amount of evidence available suggests that harm reduction interventions do not deter 
smokers from wishing to quit. More evidence of smokers’ views is likely to be provided within 
the barriers and facilitators review (Review 4). 
 Longer-term NRT use appears to be well tolerated over periods between six months and five 
years with severe side effects being relatively rare. 
Further research is needed in a number of areas: the differential effects for socio-economic and ethnic 
groups, the impact of different NRT combinations and the efficacy of e-cigarettes, the effect of 
intensity of the intervention.  
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Dr Bjorn Fossum, Sophiahemmet University College, Stockholm 
Dr Dorothy Hatsukami, Associate Director of Cancer Prevention and Control, Masonic Cancer 
Center, University of Minnesota 
Dr Richard Hurt, Director, Mayo Clinic Nicotine Dependence Center, Minnesota 
Dr Carlos Jimenez-Ruiz, Public Health Institute, Madrid 
Dr Adrian Kelly, Centre for Youth Substance Abuse Research, University of Queensland, Brisbane 
Dr Charlotta Pisinger, Research Centre for Prevention and Health, Capital Region of Denmark 
Professor Riccardo Polosa, Centre for Tobacco Research, University of Catania, Italy 
Dr Thordis Thomsen, Department of Anaesthesiology, Herlev University Hospital  
Professor Melanie Wakefield, Director of the Centre for Behavioural Research in Cancer, Cancer 
Council Victoria, Australia 
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